

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05758 A2(51) International Patent Classification⁷: C07D 209/00

40 Fountainhead Road, Apt. 1211, Toronto, Ontario M3J 2V1 (CA).

(21) International Application Number: PCT/CA00/00831

(22) International Filing Date: 14 July 2000 (14.07.2000)

(74) Agent: RIDOUT & MAYBEE; Ridout & Maybee, 150 Metcalfe Street, 19th Floor, Ottawa, Ontario K1P 1P1 (CA).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/354,091 15 July 1999 (15.07.1999) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(72) Inventors; and




(75) Inventors/Applicants (*for US only*): EDWARDS, Louise [CA/CA]; 35 Front Street South, Apt. 2008, Mississauga, Ontario L5H 2C6 (CA). ISAAC, Methvin [KN/CA]; 10 Markbrook Lane, Apt. 1507, Etobicoke, Ontario M9V 3E5 (CA). MADDAFORD, Shawn [CA/CA]; 150 Lakeshore Road West, Apt. 208, Mississauga, Ontario L5H 3R2 (CA). SLASSI, Abdelmalik [CA/CA]; 3237 Cambourne Crescent, Mississauga, Ontario L5N 5G4 (CA). XIN, Tao [CN/CA];(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

[Continued on next page]

(54) Title: HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MIGRAINE



(57) Abstract: Described herein are compounds useful in the treatment of migraine, which have general formulae (I), (II), (III) and (IV), wherein : W is a CH group or an N atom ; Z is N or C-R₄; B and D are selected independently from CH and N, with the proviso that at least one of B and D is CH and with the further proviso that one of B and D can represent N only when W and Z are both other than N; A is a group of Formula (II), (III) or (IV), such that group A contains at least 1 N atom ; NR₇ is either -NH- or -N=--- is a single or double bond ; X is an N atom, a CH group or a C(OH) group when --- is a single bond; or, when --- is a double bond, a C atom; Y is an NH, N-alkyl, N-benzyl or CH₂ group; U and V each represent an N atom or a CH group, with the proviso that both cannot be N; a and b are, independently, 0 or 1; c is an integer from 0 to 3; d is an integer from 1 to 3; e is an integer from 1 to 2; f is an integer from 0 to 3; g is an integer from 3 to 6 and h is an integer from 2 to 3; such that the sum of c and d is at least 2 and the sum of e and f is at least 2; R₁ is selected from the group consisting of H, alkyl, alkyloxy, alkanoyl, aminoalkylenyl, alkylaminoalkylenyl, a hydroxyalkylenyl group, an alkyloxyalkylenyl group, a cycloalkyl group, a cycloalkylalkylenyl group, a heterocycloalkyl group, a heterocycloalkylalkylenyl group, an aryl group, a heterocycloaryl group, an amido group, a thioamido group, an arylcarbonyl group and an arylsulfonyl group; R₂ and R₃ are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl and optionally-substituted benzyl; or R₂ and R₃, together with the nitrogen atom to which they are attached, may form a mono- or bi-cyclic group containing up to 10 carbon atoms and which, in addition, may contain a second heteroatom selected from the group consisting of N, S and O, and which may contain one or more substituents selected from the group consisting of alkyl, hydroxy, hydroxymethyl, alkyloxymethyl, amino and substituted amino; R₄ is selected from the group consisting of H, alkyl and cycloalkyl; CR₂ represents a group selected from -CH₂-, CH(OH)-, -C(O)-, -CH(alkyl)- and -CH(alkyloxy)-; R₆ is selected from the group consisting of H, alkyl, aryl, halogen, hydroxy, alkyloxy, amino, monoalkylamino and di-substituted alkylamino; and salts and solvates thereof.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Heterocyclic Compounds for the Treatment of Migraine

Field of the Invention

This invention relates to certain indole and indazole compounds, to
5 pharmaceutical and diagnostic compositions containing them and to their
medical use, particularly in the treatment or diagnosis of CNS conditions such
as migraine.

Background to the Invention

10 Through its interaction with receptors found on neuronal and other cells, 5-
hydroxytryptamine (5-HT, or serotonin) mediates a variety of physiological
effects. Imbalances in this interaction are believed to be responsible for such
conditions as anxiety, hallucination, migraine, chemotherapy-induced nausea
and for disorders in sexual activity, cardiovascular activity and
15 thermoregulation, amongst others. From an improved understanding of the 5-
HT receptor population it is apparent that these effects are mediated
selectively through individual types and subtypes of the 5-HT receptors.
Migraine, for example, has been treated with ergotamine, dihydroergotamine,
methylsergide and, most recently, sumatriptan, all of which presumably act at
20 the 5-HT_{1D} receptor subtype.


Current treatments for migraine, including sumatriptan, continue to have
unwanted side effects. These include coronary vasospasm, hypertension and
angina. Recent evidence suggests that the observed sumatriptan-mediated
25 contraction of coronary arteries may be due to the stimulation of the 5-HT_{1B}
(formerly 5-HT_{1Dβ}) subtype of the 5-HT receptors (Kaumann, A. J. Circulation,
1994, 90:1141-1153).

Given the physiological and clinical significance of the 5-HT_{1D} receptor, and
30 the potential side effect liability of stimulation of the 5-HT_{1B} receptor, it would
be desirable to provide compounds that bind with high affinity to the 5-HT_{1D}
receptor. Such compounds would be medically useful, for example, to treat


indications for which administration of a 5-HT_{1D} ligand is indicated, such as migraine. Such compounds could also be used diagnostically, for example, to identify these receptors and to screen drug candidates.

5 Summary of the Invention


It has been found that compounds of Formula I,




Formula I



Formula II



Formula III



Formula IV

wherein :

- 10 W is a CH group or a N atom ;

Z is N or C-R4;

B and D are selected independently from CH and N, with the proviso that at least one of B and D is CH and with the further proviso that one of B and D can represent N only when W and Z are both other than N;

- 15 A is a group of Formula II, III or IV, such that group A contains at least 1 N atom ;

NR7 is either -NH- or -N=

--- is a single or double bond ;

X is a N atom, a CH group or a C(OH) group when --- is a single bond; or,

- 20 when

--- is a double bond, a C atom ;

Y is an NH, N-alkyl, N-benzyl or CH₂ group ;

U and V each represent a N atom or a CH group, with the proviso that both cannot be N ;

- 25 a and b are, independently, 0 or 1 ; c is an integer from 0 to 3 ; d is an integer from 1 to 3 ; e is an integer from 1 to 2 ; f is an integer from 0 to 3 ; g is an

integer from 3 to 6 and h is an integer from 2 to 3 ; such that the sum of c and d is at least 2 and the sum of e and f is at least 2;

5 R₁ is selected from the group consisting of H, alkyl, alkyloxy, alkanoyl, aminoalkylenyl, alkylaminoalkylenyl, a hydroxyalkylenyl group, an alkyloxyalkylenyl group, a cycloalkyl group, a cycloalkylalkylenyl group, a heterocycloalkyl group, a heterocycloalkylalkylenyl group, an aryl group, a heterocycloaryl group, an amido group, a thioamido group, an arylcarbonyl group and an arylsulfonyl group ;

10

R₂ and R₃ are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl and optionally-substituted benzyl ; or R₂ and R₃, together with the nitrogen atom to which they are attached, may form a mono- or bi-cyclic group containing up to 10 carbon atoms and which, in addition, may
15 contain a second heteroatom selected from the group consisting of N, S and O, and which may contain one or more substituents selected from the group consisting of alkyl, hydroxy, hydroxymethyl, alkyloxymethyl, amino and substituted amino ;

20 R₄ is selected from the group consisting of H, alkyl and cycloalkyl ;

CR₅ represents a group selected from -CH₂-, CH(OH)-, -C(O)-, -CH(alkyl)- and
-CH(alkyloxy)- ;

25

R₆ is selected from the group consisting of H, alkyl, aryl, halogen, hydroxy, alkyloxy, amino, monoalkylamino and di-substitutedalkylamino;

and salts and solvates thereof, bind to the Serotonin 5-HT_{1D} receptor and are,
30 therefore, useful, in accordance with one aspect of the invention, for the treatment of diseases such as migraine.

In another aspect of the invention, compounds of Formula I, and radio-labelled forms thereof, are also useful as a pharmacological tool for the identification of other compounds, including potential drug candidates, which bind to the 5-HT_{1D} receptor.

5

Radio-labelled forms of compounds of Formula I are also useful as diagnostic tools for the identification of 5-HT_{1D} binding sites *in vitro*.

In another aspect, the present invention provides compounds which bind
10 selectively to the 5-HT_{1D} receptor, relative particularly to the 5-HT_{1B} receptor.

According to another aspect of the invention there are provided compositions comprising a compound of Formula I and a carrier, either for use as reagents, for example in the identification of 5-HT_{1D} receptors or 5-HT_{1D} receptor
15 ligands, or for pharmaceutical use to treat conditions where stimulation of the 5-HT_{1D} receptor is indicated.

In another aspect of the present invention, there is provided a method effective to treat medical conditions for which stimulation of the 5-HT_{1D} receptor is
20 indicated, such as migraine.

These and other aspects of the present invention are described in greater detail hereinbelow.

25 Detailed Description and Preferred Embodiments

The term "alkyl" as used herein means, unless otherwise stated, straight and branched chain alkyl radicals containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, t-butyl and the like.

30 The terms "alkylene" and "alkylenyl" as used herein means straight or branched chain divalent, i.e., bridging, alkyl chains containing from one to six

carbon atoms and includes methylene, e.g., -CH₂-, ethylene, propylene, butylene and the like.

The term "alkenyl" as used herein means straight and branched chain unsaturated radicals containing from one to six carbon atoms and includes
5 allyl, propenyl, isopropenyl, pentenyl and the like.

The term "cycloalkyl" as used herein means a monocyclic ring system containing up to 8 atoms or a bicyclic ring system containing up to 12 atoms, including "heterocycloalkyl" ring systems which may contain up to two
10 heteroatoms selected from the group consisting of N, S and O, and includes cyclopropyl, cyclohexyl, bicyclo[3.2.1]octyl, bicyclo[4.3.2]undecyl, aziridinyl, pyrrolidinyl, piperidinyl, troponyl, azabicyclo[2.2.2]octyl, tetrahydropyranyl, pyranyl, thiopyranyl, tetrahydrothiopyranyl, morpholinyl and the like, which ring system may be unsaturated and/or substituted. The terms "cycloalkyl-
15 alkylenyl" and "heterocyclo-alkylenyl" refer to rings systems of the type just described that are further substituted by a bridging alkylenyl group such as methylenyl and ethylenyl, and includes such groups as cyclohexyl-1-methylenyl, tetrahydropyranyl-4-ethylenyl, and the like. In the context of these definitions, the term "group" refers to a substituent as noted, which may
20 be further substituted by one or two substituents selected from halo, hydroxy, alkyl, alkoxy, thioalkyl and trifluoroalkyl. For instance, a heterocycloalkyl such as pyrrolidinyl is referred to as a heterocycloalkyl group when substituted by methyl, e.g. to yield N-methyl-pyrrolidinyl.

25 The term "alkyloxy" as used herein means straight and branched chain alkyloxy radicals containing from one to six carbon atoms and includes methoxy, ethoxy, propyloxy, isopropyloxy, *t*-butoxy and the like.

The term "alkanoyl" as used herein means straight and branched chain
30 alkanoyl radicals containing from one to six carbon atoms and includes acetyl, propionyl, pivaloyl and the like.

The term "aminoalkylenyl" as used herein means straight and branched chain amino-substituted alkyl or alkylenyl radicals containing from one to six carbon atoms and includes aminomethyl, aminoethyl, aminobutyl and the like. An aminoalkylenyl group may be optionally substituted at the amine function by
5 one or two groups selected independently from alkyl and alkanoyl (yielding an alkylaminoalkylenyl and an alkanoylaminoalkylenyl, respectively), and includes for instance N,N-dimethylaminoethyl; N-ethyl-N-methyl-aminopropyl, and N-ethylaminobutyl groups as well as groups such as N-acetyl-N-methyl-aminoethyl; N-butyryl-N-methyl-aminoethyl; N-acetyl-N-ethyl-aminopropyl,
10 and the like.

The term "alkanoylamino" as used herein means straight and branched chain alkanoyl-substituted amino groups such as acetylamino, butyrylamino and the like.

15

The terms "aryl" and "heteroaryl" as used herein mean an optionally substituted aromatic group which, in the case of a heteroaryl, can contain up to 2 heteroatoms, wherein the optional substituents are independently selected from 1-4 members of the group consisting of halo, hydroxy, alkyl,
20 alkoxy, thioalkyl and trifluoromethyl, and includes phenyl, naphthyl, indanyl, indolyl, quinolyl, furyl, thienyl and the like.

The terms "arylalkylenyl" and "heteroarylalkylenyl" as used herein refer to an optionally substituted aryl or a heteroaryl group in which an alkylenyl bridge
25 couples the aryl or heteroaryl to another group, and includes benzyl, phenethyl, and the like.

The term "halo" as used herein means halogen, and includes fluoro, chloro, bromo, iodo and the like, in both radioactive and non-radioactive forms.

30

The term "optionally substituted benzyl" as used herein means an unsubstituted benzyl radical or a benzyl radical substituted on the phenyl ring

with 1-3 substituents independently selected from halo, OH, SH, alkyl, alkyloxy, alkylthio, CF₃ and CF₃O.

5 The term "amido group" refers to the amido group of the formula R'R"N-C(O)- in which R' and R" are independently selected from H and alkyl.

The term thioamido group refers to the thioamido group of the formula R'R"N-C(S)- wherein R' and R" are as just described.

10 The term "pharmaceutically acceptable salt" means an acid addition salt which is compatible with the treatment of patients.

A "pharmaceutically acceptable acid addition salt" is any non-toxic organic or inorganic acid addition salt of the base compounds represented by Formula I or any of their intermediates. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include mono-, di- and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluenesulfonic and methanesulfonic acids. Either the mono- or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of compounds of Formula I are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection criteria for the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts e.g. oxalates may be used, for example, in the isolation of compounds of Formula I for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.

15
20
25
30

The term "solvate" means a compound of Formula I, or a pharmaceutically acceptable salt of a compound of Formula I, wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent is physiologically tolerable at the dosage administered. Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a hydrate.

The term "stereoisomers" is a general term for all isomers of a molecule which differ only in the orientation of their atoms in space. It includes image isomers (enantiomers), geometric (cis/trans) isomers and isomers of compounds with more than one chiral centre which are not mirror images of one another (diastereomers).

The term "treat" or "treating" means to alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms of the named disorder or condition.

The term "therapeutically effective amount" means an amount of the compound that is effective in treating the named disorder or condition. An amount "effective to stimulate the 5-HT_{1D} receptor" is an amount that yields a measurable increase in 5-HT_{1D} receptor activity, as measured using an assay and end-point appropriate for that measurement. For instance, amounts effective to stimulate the 5-HT_{1D} receptor for purposes of therapy are those amounts that, following administration, yield a detectable improvement in the symptoms associated with the given disease or condition under treatment. Where the 5-HT_{1D} stimulation sought is in the context of an in vitro assay, for instance during screening of compounds for their ability to compete with a present compound, then the 5-HT_{1D} receptor stimulation can most suitably be measured more directly, as a decrease in the production of adenylyl cyclase, revealed for instance by a decrease in the levels of cAMP.

The term "pharmaceutically acceptable carrier" means a non-toxic solvent, dispersant, excipient, adjuvant or other material which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to the patient. One example of
5 such a carrier is pharmaceutically acceptable oil typically used for parenteral administration.

The present invention includes within its scope prodrugs of the compounds of Formula I. In general, such prodrugs will be functional derivatives of a
10 compound of Formula I which are readily convertible *in vivo* into the compound from which it is notionally derived. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985.

15 Compounds of Formula I bind to the serotonin 5-HT_{1D} receptor. Preferred compounds of Formula I bind selectively (for example with 10-fold selectivity) to the serotonin 5-HT_{1D} receptor, relative, particularly, to the serotonin 5-HT_{1B} receptor, as judged by *in vitro* binding affinities using, for example, the assay exemplified herein. More preferred compounds are those which bind with at
20 least 10-fold selectivity to the 5-HT_{1D} receptor, relative to the 5-HT_{1B} receptor. Most preferred are those compounds that bind with at least 40-fold selectivity to the 5-HT_{1D} receptor, relative to the 5-HT_{1B} receptor.

In embodiments of the present invention, compounds of Formula I are those
25 in which W and Z, as well as B and D, are selected to form a ring system, substituted by A, R1, R4 and R6, which is selected from indole, indoline, indazole, benzotriazole, benzimidazole, 7-aza-indole (also referred to as 1H-pyrrolo-[2,3-b]-pyridine) and 5-aza-indole (also referred to as 1H-pyrrolo-[3,4-c]-pyridine). In specific embodiments, all of B, D, W and Z are selected to
30 form a ring system that is either indole or indazole.

In other embodiments of the present invention, R6 is selected from H and alkyl, and R4 is H.

Thus, in specific embodiments, B, D, W, Z, R4 and R6 are selected to form a
5 ring system selected from indole and indazole.

In other embodiments, R1 is desirably selected from H, alkyl, aminoalkylenyl, alkylaminoalkylenyl, alkenylaminoalkylenyl, amido unsubstituted or substituted by one or two alkyl groups, thioamido unsubstituted or substituted
10 by one or two alkyl groups, and a substituted or unsubstituted group which is cycloalkyl, cycloalkyl-alkylenyl, heterocycloalkyl, heterocycloalkyl-alkylenyl aryl, arylalkenyl, heteroaryl or heteroarylalkenyl. When R1 is alkyl, preferred groups include methyl, ethyl and propyl, especially isopropyl. When R1 is aminoalkyl, a preferred group is aminoethyl. When R1 is alkylaminoalkyl,
15 preferred groups include N,N-dimethylaminoethyl, N,N-diethylaminoethyl, and N-isopropyl-aminoethyl. When R1 is an alkenylaminoalkyl, a preferred group is N-prop-1-enyl-aminoethyl. When R1 is an amido group or a thioamido group, preferred groups are amido, N,N-dimethylamido, and thioamido. When R1 is a hydroxyalkylenyl group, a preferred group is hydroxyethylenyl. When
20 R1 is cycloalkyl or heterocycloalkyl, specific groups include cyclohexyl, tetrahydropyranyl, and tetrahydrothiopyranyl. When R1 is an aryl or heteroaryl, preferred groups include phenyl, phenyl substituted by alkyl such as methyl, or by halogen such as fluoro, and 3-pyridyl and 4-pyridinyl, as well as thioimidazole. R1 may also be benzoyl or tosyl. In other embodiments, R1
25 may be an alkyl which is C(1-12)alkyl, such as C(6-9)alkyl, including hexyl, heptyl, octyl and preferably nonyl.

In a preferred embodiment, R1 is selected from alkyl and heterocycloalkyl. In particularly preferred embodiments, R1 is alkyl, and especially isopropyl. In
30 other particularly preferred embodiments, R1 is heterocycloalkyl, and especially tetrahydropyranyl.

Thus, in specific preferred embodiments, the ring system formed by selection of B, D, W, Z, R4 and R6, is an A-substituted ring system that is substituted by an R1 group that is alkyl, and particularly isopropyl, including a 1-isopropyl-indole group and a 1-isopropyl-indazole group. In other specific preferred
5 embodiments, the A-substituted ring system so formed is substituted by an R1 group that is heterocycloalkyl, including particularly a tetrahydropyranyl group, to form a 1-tetrahydropyran-4-yl-indole or a tetrahydropyran-4-yl-indazole group.

10 In other embodiments of the invention, Group A is a group of Formula II, III or IV. When Group A is of Formula II, the Formula II substituents desirably are selected to form a (mono- or di-) substituted aminoalkylenyl or N-cycloalkyl or N-cycloalkylalkylenyl group such as N,N-dimethylaminoethyl, N,N-diethylaminoethyl, N-methyl-N-ethylaminoethyl, N-isopropylaminoethyl, N,N-dipropylaminoethyl, N-cyclopropylaminoethyl, N-cyclopropylmethylaminoethyl,
15 N-methyl-N-cyclopropylamino, pyrrolidinoethyl, pyrrolinoethyl, piperidinoethyl, morphilinoethyl, thiomorpholinoethyl, piperazinoethyl.

Preferably, A is a group of Formula IV, and NR7 is -NH- when a is 1.
20 Preferred groups of Formula IV include an 1-azabicyclo[4.3.0]nonanyl group, an 1-azabicyclo[4.4.0]decanyl group, a 1,4-diazabicyclo[4.3.0]nonanyl group or a 1,4-diazabicyclo[4.4.0]decanyl group .

More preferably, A is a group of Formula III, and NR7 is -NH- when a is 1.
25 Preferred groups of Formula III are (pyrrolidin-2-yl)methyl, N-methyl(pyrrolidin-2-yl)methyl, tetrahydropyridin-4-yl, tetrahydropyridin-3-yl and piperaziny.

Most preferably, A is a group of Formula II, such as dialkylaminoalkyl (for
30 example, a 2-(diethylamino)ethyl group).

In the case where A is a Formula II group, then the compounds of the present invention, as defined by general Formula I, exclude the following compounds: 6-(2-methyl-2-aminoethyl)-1H-indole, 6-(2-aminoethyl)-1-methyl-indole, 6-(N,N-Di-n-propylaminoethyl)-1H-indole, 6-(2-n-propyl-2-n-propylaminoethyl)-1H-indole, and 6-(2-methyl-2-N,N-dimethylaminoethyl)-1H-indole.

Specific embodiments of the invention include :

- 10 6-(2-(N,N-Dimethylamino)ethyl)-1H-indole ;
- 6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-indole ;
- 6-(2-(N,N-Diethylamino)ethyl)-1H-indole ;
- 6-(2-(N,N-Diethylamino)ethyl)-1-isopropyl-indole ;
- 6-(2-(N,N-Diethylamino)ethyl)-1-dimethylaminocarbonyl-indole ;
- 15 6-(2-(N,N-Dimethylaminoethyl)-1-(tetrahydrothiopyran-4-yl)-indole ;
- 6-(2-(N,N-Dimethylaminoethyl)-1-(tetrahydropyran-4-yl)-indole ;
- 6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-indazole ;
- 6-(2-(N,N-Diethylamino)ethyl)-1-isopropyl-indazole ;
- 6-(2-N-pyrrolidinyl)ethyl)-1-isopropyl-indazole;
- 20 6-(2-pyrrolin-3-yl)ethyl-1-isopropyl-indazole;
- (R)-6-(2-(N-(3-tert-butoxycarbonylamino)pyrrolidinyl)ethyl)-1-(2-propyl)-1H-indazole
- (S)-6-(2-(N-(3-tert-butoxycarbonylamino)pyrrolidinyl)ethyl)-1-(2-propyl)-1H-indazole
- 25 (R)-6-(2-(N-(2-hydroxymethyl)pyrrolidinyl)ethyl)-1-(2-propyl)-1H-indazole
- (S)-6-(2-(N-(2-hydroxymethyl)pyrrolidinyl)ethyl)-1-(2-propyl)-1H-indazole
- 6-(2-(N-cyclopropylamino)ethyl)-1-(2-propyl)-1H-indazole
- 6-(2-cyclopropylamino)ethyl)-1-isopropyl-indazole ;
- 6-(2-(N-cyclopropylmethylamino)ethyl)-1-(2-propyl)-1H-indazole;
- 30 6-(2-(N-methylpiperazino)ethyl)-1-(2-propyl)-1H-indazole;
- 6-(2-methylcyclopropylamino)ethyl)-1-isopropyl-indazole ;
- 6-(N-methylpiperazinyl)-1-isopropyl-indazole ;

- 6-(2-Diethylaminoethyl)-1-(4-fluorophenyl)-indole ;
 6-(2-Diethylaminoethyl)-1-(3-thienyl)-indole ;
 6-(2-(N,N-Diethylaminoethyl)-1-(tetrahydropyran-4-yl)-indole ;
 6-(N-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1-isopropyl-indole ;
 5 6-(2-Diethylaminoethyl)-1-phenylsulfonamide-indole ;
 6-(4-Hydroxy-N-methyl-piperidin-4-yl)-1-N,N-dimethylethylamine-indole ;
 6-(N-methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-N,N-dimethylethylamine-indole ;
 6-(N-methyl-piperidin-4-yl)-1-N,N-dimethylethylamine-indole ;
 6-(N-methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(ethylamine-2-ol)-indazole ;
 10 6-(N-methyl-piperidin-4-yl)-1-(ethylamine-2-ol)-indazole ;
 6-[4-Hydroxy-1-azabicyclo[4.3.0]nonan-4-yl]-indole ;
 6-[4-Hydroxy-1-methyl-piperidin-4-yl]-indole ;
 6-[N-methyl-1,2,5,6-tetrahydropyridin-4-yl]-indole ;
 6-[3,4-anhydro-1-azabicyclo[4.3.0]nonan-4-yl]-indole ;
 15 6-[4,5-anhydro-1-azabicyclo[4.3.0]nonan-4-yl]-indole ;
 6-[N-Methyl-1,2,5,6-tetrahydropyridin-4-yl]-1-isopropyl-indole ;
 6-[1-Azabicyclo[4.3.0]nonan-4-yl]-indole ;
 6-[3,4-Anhydro-1-azabicyclo[4.3.0]nonan-4-yl]-1-isopropyl-indole ;
 1-(4-Fluorophenyl)-6-(N-methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole ;
 20 1-..6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-thienyl)-indole ;
 6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-pyridyl)-indole ;
 6-[1-Azabicyclo[4.3.0]nonan-4-yl]-1-(4-pyridinyl)-indole ;
 6-(2-Dimethylaminoethyl)-1-(3-pyridinyl)-indole ;
 6-(2-Dimethylaminoethyl)-1-(3-thienyl)-indole ;
 25 6-(2-Dimethylaminoethyl)-1-(4-fluorophenyl)-indole ;
 6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(2-thiazolyl)-indole ;
 1-Dimethylaminocarbonyl-6-[N-methyl-1,2,5,6-tetrahydro-pyridin-4-yl]-indole ;
 6-[4-Hydroxy-1-methyl-piperidin-4-yl]-1-isopropyl-indole ;
 6-((N-Benzoyloxycarbonyl)propyl)-indole ;
 30 6-[(α -Hydroxy- α -(2-Pyrrolidinyl))methyl]-indole ;
 1-isopropyl-6-(1-methylpiperidin-3-yl)-1*H*-indole

- 1-isopropyl-6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1*H*-indole
 1-triisopropylsilyl-6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1*H*-indole
 6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1*H*-indole
 6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1-(3-thienyl)-1*H*-indole
 5 1-(4-fluorophenyl)-6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1*H*-indole
 1-(pyridin-3-yl)-6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1*H*-indole
 6-((2-Pyrrolidinyl)methyl)-1-isopropyl-indole ;
 6-(*N*-methyl-(2-Pyrrolidinyl)methyl)-1-*n*-propyl-indole ;
 1-propyl-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]-1*H*-indole;
 10 1-dodecyl-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]-1*H*-indole
 1-(pyridin-4-yl)-6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1*H*-indole;
 1-benzenesulfonyl-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]-1*H*-indole
 15 1-(tetrahydro-2*H*-thiopyran-4-yl)-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]-1*H*-indole
 6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]-1-(tetrahydro-2*H*-pyran-4-yl)indoline
 6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]-1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-indole
 1-(1-methylpiperidin-4-yl)-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]indoline
 20 1-(1-methylpiperidin-4-yl)-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]indole
 1-(1-benzylpiperidin-4-yl)-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]indoline
 1-(1-propylpiperidin-4-yl)-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]indole
 1-cyclohexyl-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]indoline
 1-cyclohexyl-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl]indole
 25 1-isopropyl-6-[[*(2S)*-pyrrolidin-2-yl]methyl]-1*H*-indole
 1-isopropyl-6-(1-methylpiperidin-4-yl)-1*H*-indole
 1-benzyl-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1*H*-indole
 6-(*N*-methylpiperazinyl)-indole ;
 30 1-Isopropyl-6-(*N*-methylpiperazinyl)-indole ;
 1-Isopropyl-6-(*N*-methylhomopiperazinyl)-indole ;
 6-(1,3-Diazabicyclo-[4,4,0]-decan-3-yl)-1-isopropyl-indole ;
 1-Isopropyl-6-(3-methylpiperazinyl)-indole ;
 1-Isopropyl-6-(4-methylpiperazinyl)-indole ;
 35 1-(4-Fluorophenyl)-6-(4-methylpiperazinyl)-indole ;
 6-(4-methylpiperazinyl)-1-(3-thiazolyl)-indole and

6-(4-methylpiperazinyl)-1-(3-thienyl)-indole.

Preferred embodiments of the invention include :

- 5 6-[4-Hydroxy-1-methyl-piperidin-4-yl]-indole ;
6-[N-Methyl-1,2,5,6-tetrahydropyridin-4-yl]-indole ;
6-[N-Methyl-1,2,5,6-tetrahydropyridin-4-yl]-1-isopropyl-indole ;
1-(4-Fluorophenyl)-6-(N-methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole ;
6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-thienyl)-indole ;
10 6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-pyridyl)-indole ;
6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(2-thiazolyl)-indole ;
1-N,N-Dimethylaminocarbonyl-6-[N-methyl-1,2,5,6-tetrahydropyridin-4-yl]-
indole ;
6-[4-Hydroxy-1-methyl-piperidin-4-yl]-1-isopropyl-indole ;
15 6-((N-Benzoyloxycarbonyl)propyl)-indole ;
6-[(α -Hydroxy- α -(2-pyrrolidinyl))methyl]-indole ;
6-((2-Pyrrolidinyl)methyl)-indole ;
6-(N-methylpiperazinyl)-indole ;
1-Isopropyl-6-(N-methylpiperazinyl)-indole ;
20 1-Isopropyl-6-(N-methylhomopiperazinyl)-indole ;
1-Isopropyl-6-(3-methylpiperazinyl)-indole ;
1-Isopropyl-6-(4-methylpiperazinyl)-indole ;
1-(4-Fluorophenyl)-6-(4-methylpiperazinyl)-indole ;
6-(4-Methylpiperazinyl)-1-(3-thiazolyl)-indole and
25 6-(4-Methylpiperazinyl)-1-(3-thienyl)-indole.

More preferred embodiments of the invention include :

- 6-(2-(N,N-Dimethylamino)ethyl)-1H-indole ;
30 6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-indole ;
6-(2-(N,N-Diethylamino)ethyl)-1-isopropyl-indole ;
6-(2-(N,N-Diethylamino)ethyl)-1-dimethylaminocarbonyl-indole ;

- 6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydrothiopyran-4-yl)-indole ;
6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydropyran-4-yl)-indole ;
6-(2-(N,N-Dimethylamino)ethyl)-1-(3-pyridinyl)-indole ;
6-(2-(N,N-Dimethylamino)ethyl)-1-(3-thienyl)-indole and
5 6-(2-(N,N-Dimethylamino)ethyl)-1-(4-fluorophenyl)-indole.

Some of the compounds of Formula I may have at least one asymmetric centre. Where the compounds according to the invention have one asymmetric centre they may exist as enantiomers. Where the compounds
10 according to the invention possess two or more asymmetric centres, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.

15 Acid addition salts of the compounds of Formula I are most suitably formed with pharmaceutically acceptable acids, and include, for example, those formed with inorganic acids e.g. hydrochloric, sulphuric or phosphoric acids and organic acids e.g. succinic, maleic, acetic or fumaric acid. Other non-pharmaceutically acceptable salts e.g. oxalates may be used, for example, in the isolation of
20 compounds of Formula I for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.

The conversion of a given compound salt to a desired compound salt is achieved by standard techniques in which an aqueous solution of the given salt
25 is treated with a solution of base e.g. sodium carbonate, potassium hydroxide to liberate the neutral compound which is then extracted into an appropriate solvent, such as ether. The neutral compound is then separated from the aqueous portion, dried, and treated with the requisite acid to give the desired salt.

30

Also included within the scope of the invention are solvates of the compounds of the invention. The formation of a solvate will vary depending on the

compound and solvent used. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions.

5

Prodrugs of compounds of the invention may be conventional esters formed with available hydroxyl (or thiol) or carboxyl groups. For example, when one of R^3 or R^4 is OH in a compound of Formula I, it may be acylated using an activated acid in the presence of a base and, optionally, in inert solvent (e.g. an acid chloride in pyridine). Some common esters which have been utilized as


10

In accordance with another aspect of the invention, the compounds of the invention can be prepared by processes analogous to those established in the art.

15

For example, indoles of Formula I where A is a (dimethylamino)ethyl group can be prepared as shown in Scheme 1, below :


20



Reagents : (i) Me₂NH, THF ; (ii) LiAlH₄, THF, reflux ; (iii) Alkylation : NaH, K₂CO₃, R₁X, toluene, DMF, reflux ;
Arylation : K₂CO₃, ArX, Cu, CuBr, NMP, 165°


Scheme 1

Alternatively, such compounds may be made according to Scheme 2, below :



Scheme 2

Indoles of Formula I where A is a group of Formula II and h is 2 may also be
 5 prepared according to Scheme 3, below :




Reagents : (i) DMF-DMA, 140°; (ii) MeOH, TMSCl; (iii) Na₂S₂O₄, EtOH; (iv) ketone, NaBH(OAc)₃, MeOH; (v) anhyd. HCl, MeOH, reflux; (vi) Pd₂(DBA)₃, BINAP, KHDMS, dioxane, NN-DMA, 100°; (vii) LiAlH₄, THF, reflux; (viii) ketone, TFA, AcOH, 100°

Scheme 3

Indazoles of Formula 1 where where A is a group of Formula II, h is 2 and R₁ is an alkyl group can also be prepared according to Scheme 4, below :


5



Reagents : (i) NaNO₂, DMF / H₂O, KI; (ii) NaH, DMF / alkyl halide; (iii) Pd₂(DBA)₃, S-BINAP, KHDMS, N,N-Dimethylacetamide, dioxane; (iv) LiAlH₄, THF

Scheme 4

Compounds where A is a group of Formula II and h is 3 can be prepared as shown in Scheme 5, below :




Reagents (i) $\text{Pd}(\text{OAc})_2$, PPh_3 , DMF ; (ii) H_2 , Pd/C, EtOH ; (iii) LiAlH_4 , THF ; (iv) MsCl , Et_3N , CH_2Cl_2 ; (v) $\text{R}_3\text{R}_2\text{NH}$, THF, reflux

Scheme 5


5

Indoles of Formula I (i.e. compounds where X is CH) where a and b are both zero and A is a group of Formula III or IV can be prepared by a number of routes. For example, as shown in Scheme 6 , below :



Scheme 6

Indoles of Formula I in which a is zero and b is 1 may be prepared as shown below :




Scheme 7

The product from the above reactions can be further modified, for example, to introduce substituents at the 1 or 3 positions of the ring, as previously described.

- 5 Compounds of Formula I in which A is of Formula II or III can be prepared as shown below:

10 Compounds of Formula I in which a is 1 and b is 0 can be prepared as shown below :




Reagents : (i) NaH, DMF, 0°, (tPr)₃Si-Cl ; (ii) amine, NaOtBu, Pd(OAc)₂, tBu₃P, xylene, 120° ; (iii) TBAF, THF ;
 (iv) Alkylation : NaH, K₂CO₃, R₁X, toluene, DMF, 100° ; Arylation : K₂CO₃, ArX, Cu, CuBr, NMP, 165° ;
 (v) Alkylation : NaH, K₂CO₃, R₁X, toluene, DMF, 100° ; (vi) as (ii) ; (vii) as (ii).

Scheme 8


15 It should be noted that when R₄ is a group other than H then the substituent may be present at the beginning of the synthetic pathway (for example, in compounds 1, 4, 10 etc.) or, alternatively, it can be introduced at an intermediate stage, or at the end of, the synthesis. Also, any substituents at the 3 and 6 positions of the indole ring may be introduced in either order. The

choice of exact route used will be governed by various factors, such as the availability of starting materials. Other methods useful to produce Formula I compounds are shown below




Reagents : (i) formamidine acetate, MeOCH₂CH₂OH, reflux (ii) NaNO₂, H₂SO₄

Scheme 9



Reagents: (ii) HMDS, RCOX, THF or benzene, RT; (iii) as in schemes 2, 6, 7, 8 and example 32; (iv) NaOH, MeOH, RT;


Scheme 10



Reagents: (i) as in schemes 1, 2, 3, 4, 5, 6, 7 and 8; (ii) as in schemes 1, 2, 4, 6, 8 and example 32

Scheme 11

5



Reagents : (i) DMF-DMA, 140° ; (ii) MeOH, TMSCl; (iii) $Na_2S_2O_4$, EtOH ; (iv) ketone, $NaBH(OAc)_3$, MeOH ; (v) anhydrous HCl, MeOH, reflux ; (vi) $Pd_2(DBA)_3$, BINAP, KHDMS, dioxane, NN-DMA, 100° ; (vii) $LiAlH_4$, THF, reflux, (vi) as in schemes 1, 2, 3, 4, 5, 6, 7, and 8

Scheme 12

- 10 Similarly, it should be appreciated that one skilled in the art would realize that the sequences of reactions described in the above schemes may, at times, be varied, depending upon the exact nature of the compounds being made and chemistries involved.
- 15 In some cases the chemistries outlined above may have to be modified, for instance by use of protecting groups, to prevent side reactions due to reactive groups, such as reactive groups attached as substituents. This may be achieved by means of conventional protecting groups, as described in

Protective Groups in Organic Chemistry, ed. McOmie, J.F.W. Plenum Press, 1973; and Greene, T.W. & Wuts, P.G.M., *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991.

- 5 In another embodiment of the invention, the present compounds can be used to distinguish 5-HT_{1D} receptors from other receptor subtypes, for example glutamate or opioid receptors, within a population of receptors, and in particular to distinguish between the 5-HT_{1D} and other 5-HT receptor subtypes. The latter can be achieved by incubating preparations of the 5-HT_{1D} receptor and one of
- 10 the other 5-HT receptor subtypes (for example 5-HT_{1B}) with a 5-HT_{1D}-selective compound of the invention and then incubating the resulting preparation with a radiolabeled serotonin receptor ligand, for example [³H]-serotonin. The 5-HT_{1D} receptors are then distinguished by determining the difference in membrane-bound activity, with the 5-HT_{1D} receptor exhibiting lesser radioactivity, i.e.,
- 15 lesser [³H]-serotonin binding, than the other 5-HT receptor subtype.

- In another aspect of the invention, a compound of the invention is provided in labeled form, such as radiolabeled form, e.g. labeled by incorporation within its structure ³H or ¹⁴C or by conjugation to ¹²⁵I. In another aspect of the
- 20 invention, the compounds in labeled form can be used as competitive ligands to identify 5-HT_{1D} receptor ligands by techniques common in the art. This can be achieved by incubating the receptor or tissue in the presence of a ligand candidate and then incubating the resulting preparation with an equimolar amount of radiolabeled compound of the invention. 5-HT_{1D} receptor ligands
- 25 are thus revealed as those that are not significantly displaced by the radiolabeled compound of the present invention. Alternatively, 5-HT_{1D} receptor ligand candidates may be identified by first incubating a radiolabeled form of a compound of the invention, then incubating the resulting preparation in the presence of the candidate ligand. A more potent 5-HT_{1D} receptor ligand
- 30 will, at equimolar concentration, displace the radiolabeled compound of the invention.

A radiolabelled compound of Formula I may be prepared using standard methods known in the art. For example, tritium may be incorporated into a compound of Formula I using standard techniques, for example by hydrogenation of a suitable precursor to a compound of Formula I using
5 tritium gas and a catalyst. Alternatively, a compound of Formula I containing radioactive iodo may be prepared from the corresponding trialkyltin (suitably trimethyltin) derivative using standard iodination conditions, such as [¹²⁵I] sodium iodide in the presence of chloramine-T in a suitable solvent, such as dimethylformamide. The trialkyltin compound may be prepared from the
10 corresponding non-radioactive halo, suitably iodo, compound using standard palladium-catalyzed stannylation conditions, for example hexamethylditin in the presence of tetrakis(triphenylphosphine) palladium (0) in an inert solvent, such as dioxane, and at elevated temperatures, suitably 50-100 °C.

15 The present compounds are useful as pharmaceuticals for the treatment of various conditions in which the use of a 5-HT_{1D} ligand is indicated, such as for the treatment of migraine, cluster headache and portal tension, a condition characterized by increased portal vein blood flow and typically associated with cirrhosis of the liver.

20 For use in medicine, the compounds of the present invention can be administered in a standard pharmaceutical composition. The present invention therefore provides, in a further aspect, pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one compound of Formula I,
25 or a pharmaceutically acceptable salt, solvate or hydrate thereof, in an amount effective to stimulate the 5-HT_{1D} receptor.

The compounds of the present invention may be administered by any convenient route, for example by oral, parenteral, buccal, sublingual, nasal,
30 rectal or transdermal administration. Appropriate pharmaceutical compositions will be formulated accordingly.

Compounds of Formula I and their stereoisomers, solvates, hydrates or pharmaceutically acceptable salts for oral administration can be formulated as liquids, for example syrups, suspensions, solutions or emulsions, or as solid forms such as tablets, capsules and lozenges, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. A liquid formulation will generally consist of a suspension or solution of the compound (or pharmaceutically acceptable salt thereof) in a suitable pharmaceutical liquid carrier such as ethanol, glycerine, polyethylene glycol, oils, or water with a suspending agent (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats), preservative (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid), flavouring or colouring agent. A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into hard gelatin capsule. Alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier, for example aqueous gums, celluloses, silicates or oils, and the dispersion or suspension filled into a soft gelatin capsule.

Compounds of the present invention may be formulated for parenteral administration by injection, including using conventional catheterisation techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g. in ampoules, or in multi-dose containers, with an added preservative. Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil, and may contain formulatary agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the solution can be lyophilized and then reconstituted with a suitable solvent just prior to administration.

Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form, in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as fluorochlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomizer. Capsules and cartridges of, for example, gelatin for use in an inhaler or atomizing device may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, wherein the active ingredient is formulated with a carrier such as sugar, acacia, tragacanth, or gelatin and glycerine. Compositions for rectal administration are prepared in the form of, for example, suppositories or retention enemas, and may contain a conventional suppository base such as cocoa butter or other glycerides.

A proposed dose of the compounds of the invention for oral, buccal, sublingual or rectal administration to a human (of about 70 kg body weight) for the treatment of migraine is 0.1 mg to 500 mg, for example 0.5 mg to 100 mg, preferably 1 mg to 50 mg, of active ingredient per dose, administered up to 8 times per day, more usually 1 to 4 times per day. It will be appreciated that it may be necessary to make routine changes to the dosage depending on the age and weight of the patient as well as the severity of the condition to be

treated. It should be understood that unless otherwise indicated, the dosages are referred to in terms of the weight of the compound of Formula I calculated as the free base.

- 5 The overall daily dosage administered by injection may be in the range of 0.01 mg to 100 mg, preferably between 0.1 mg and 50 mg, e.g., between 1 mg and 25 mg, of a compound of Formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof calculated as the free base, the compound being administered 1 to 4 doses per day.

10

Aerosol formulations are preferably arranged so that each metered dose or "puff" delivered from a pressurized aerosol contains 0.1 to 10 mg of a compound of the invention, and each dose administered via capsules and cartridges in an inhaler contains 0.1 to 50 mg of a compound of the invention.

- 15 Administration may be several times daily, for example 2 to 8 times, giving for example 1, 2 or 3 doses each time. The overall daily dose by inhalation will be similar to that for oral administration.

- The compounds of the invention may, if desired, be administered in combination with one or more other therapeutic agents, such as analgesics, anti-inflammatory agents and anti-nauseants.

Experimental Examples

- 25 **Example 1 : 6-(2-(N,N-Dimethylamino)ethyl)-1H-indole (compound 2).**

- To a stirred solution of 6-Chloroacetyl-1-pivaloylindole (300mg, 1.08mmol) in THF (5ml) were added successively, at room temperature, NaHCO₃ (453.6mg, 5.4 mmol) and a solution of 2M N,N-Dimethylamine in THF (2.7ml, 5.4mmol). The reaction mixture was then refluxed for four hours. After cooling to room temperature, the mixture was diluted with water (15ml) and the organic layer extracted twice with dichloromethane (2 x 50ml). After washing sequentially with water and brine, the organic layer was dried over sodium

sulfate, and the solvent removed *in vacuo*. LiAlH₄ (10.8ml, 1M in THF, 10.8mmol) was added to a solution of the crude product in THF (5ml) and the reaction mixture heated at reflux overnight. After cooling to room temperature, the reaction mixture was quenched with Rochelle's salt (1M, 3mL) and silica gel and passed through a frit using methanolic ammonia in dichloromethane (0-10%). The 5% fraction was further purified by flash chromatography (silica gel, 3% methanolic ammonia in dichloromethane) yielding the product (176 mg, 87%) of the title product.

10

Example 2: 6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-indole (compound 3).

Sodium hydride (12.7mg, 0.531mmol) was added to an ice-cooled solution 6-(2-(N,N-Dimethylamino)ethyl)-1H-indole (50mg, 0.265mmol) in DMF (1ml).

15 After stirring for 1h at 0°C, 2-iodopropane (52.9μL, 0.530mmol) was added and the mixture stirred at 100°C overnight. The reaction mixture was then partitioned between water and dichloromethane, the organic layer washed sequentially with water and brine, dried over sodium sulfate and the solvent was removed *in vacuo*. Flash chromatography (silica gel, 7% methanolic ammonia in dichloromethane) gave the title product (10mg, 16%).

20

Example 3 : 6-(^tButyloxycarbonylmethyl)-1-trimethylacetyl-indole (compound 5).

To a solution of NiCl₂(PPh₃)₂ (68.8mg, 0.1mmol) and PPh₃ (55.6 mg, 0.2mmol) in diethyl ether (1ml) was added a 1M solution of EtMgBr (0.25ml, 0.25mmol), dropwise under argon, at 0 to 5°C. After stirring for 10mins, a 0.5M solution of ^tBuOCOCH₂ZnCl (4ml, 2mmol) was added, followed by 6-Bromo-1-trimethyl-acetyl-indole (280 mg, 1mmol). The reaction mixture was stirred at 40 to 45°C overnight, diluted with dichloromethane, washed with saturated-NH₄Cl and water, dried over anhydrous sodium sulphate and the crude product passed through a silica gel column, eluting with hexane, to give the title product (yield 233.6mg, 78%).

30

b) In a similar fashion, **6-(^tButyloxycarbonylmethyl)-1-indole** was prepared from 6-Bromo-indole (100mg, 0.51mmol), 0.5M ^tBuOCOCH₂ZnCl (3ml, 1.5mmol), NiCl₂(PPh₃)₂ (34.4mg, 0.05mmol), PPh₃(27.8 mg, 1mmol) and 1M EtMgBr (0.125 ml, 0.125mmol) to give 27mg (23% yield) of the title product.

5

Example 4 : 6-(2-Hydroxyethyl)-indole (compound 6)

A mixture of 6-(^tButyloxycarbonylmethyl)-1-trimethylacetyl-indole (233.6mg, 0.78mmol) and 1M LiAlH₄ (5 ml, 5mmol) was refluxed for 1 hr. The reaction mixture was quenched with sodium sulphate decahydrate, diluted with ethyl acetate and the crude product passed through a silica gel column, eluting with dichloromethane, to give 72.5mg (58%) of the title compound.

10

b) **6-(2-Hydroxyethyl)-indole** was prepared from 6-(^tButyloxycarbonylmethyl)-1-indole, under the same conditions.

15

Example 5 : 6-(2-(Methanesulfonyl)ethyl)-indole (compound 7).

6-(2-Hydroxyethyl)-indole (72.5mg, 0.45mmol) was mixed with Et₃N (126mg, 1.35mmol) in 2ml of dichloromethane at 0 to 5°C. Methane sulfonyl chloride (61.6mg, 0.54mmol) was added and the mixture stirred for 1hr, diluted with dichloromethane, washed with brine, dried and concentrated to give 107mg of the title compound (quantitative yield).

20

Example 6 : 6-(2-(Diethylamino)ethyl)-indole (compound 8).

A mixture of 6-(2-(Methanesulfonyl)ethyl)-indole (107mg, 0.45mmol) and diethylamine (0.4 ml) in 2ml of THF was stirred at 65°C overnight. The reaction mixture was concentrated *in vacuo* and passed through a silica gel column, eluting with 2% 2M ammonia/methanol in dichloromethane, to give the title compound, 42 mg (43% yield).

25

Example 7 : 6-(2-(Diethylamino)ethyl)-1-isopropyl-indole (compound 9, alkylation example)

30

Prepared from 6-(2-(Diethylamino)ethyl)-indole (14mg, 0.0647mmol), 2-iodopropane (44 μ l, 0.259mmol), NaH (3.1mg, 0.129mmol), K₂CO₃ (35mg, 0.259mmol) in 0.1 ml of DMF and 0.5 ml of toluene, according to example . Yield 8.5mg (51%).

5

Example 8 : 6-(2-(Diethylamino)ethyl)-1-dimethylaminocarbonyl-indole (compound 9, amidation example)

To a stirred solution of 6-(2-(Dimethylamino)ethyl)-indole (14.5mg, 0.067mmol) was added dropwise at 0°C 0.2ml (0.2mmol) of a 1M solution of NaN(TMS)₂ in THF. The reaction mixture was stirred at this temperature for another 30 min. Then 21.5mg, (0.2mmol) of dimethylcarbonyl chloride was added dropwise, and the reaction mixture stirred for another 30min before being poured into dichloromethane (10ml), and slowly quenched with water and brine. The aqueous phase was extracted twice with 15ml of dichloromethane. The organic layer was dried over Na₂SO₄, concentrated *in vacuo* and the residue purified by column chromatography on silica gel, eluting with 10% 2M ammonia/methanol in dichloromethane to give 8.3mg (42%) of the title compound.

20 **Example 9 : 4-Bromo-2-[(tetrahydropyran-4-yl)amino]-phenylacetaldehyde, dimethyl acetal (compound 14).**

2-Amino-4-bromo-phenylacetaldehyde, dimethyl acetal (500mg, 1.92mmol) and tetrahydro-4-pyranone (2.88mmol) were stirred in acetic acid (14ml), in the presence of Na₂SO₄ (2.72g), for 30 mins. Sodium triacetoxyborohydride (NaBH(OAc)₃; 1.22g, 5.77mmoles) was then added and the mixture stirred for 2hrs before being poured into an 8:1 mixture of ethyl acetate-hexanes (50 ml) and slowly quenched with saturated NaHCO₃ solution. The organic layer was dried over Na₂SO₄, concentrated *in vacuo* and the residue purified by column chromatography on silica gel, eluting with ethyl acetate: hexanes (1:5), to give the title compound (522.8 mg, 79% yield).

30

In a similar fashion the following compounds were prepared :

b) **4-Bromo-2-[(tetrahydrothiopyran-4-yl)amino]-phenylacetaldehyde, dimethyl acetal** ; from 2-Amino-4-bromo-phenylacetaldehyde, dimethyl acetal (500mg, 1.92mmol) tetrahydrothiopyran-4-one (2.88mmol), acetic acid (14ml) and NaBH(OAc)₃ (1.22g, 5.77mmol); yield 549mg (79%);

c) **4-Bromo-2-[(N-Butoxycarbonyl-piperidin-4-yl)amino]-phenylacetaldehyde, dimethyl acetal** ; from 2-Amino-4-bromo-phenylacetaldehyde, dimethyl acetal (500mg, 1.92mmol), N-Butoxycarbonyl-4-piperidone (2.88mmol), acetic acid (14ml) and NaBH(OAc)₃ (1.2g, 5.77mmol). Yield 728mg (86%);

d) **2-[(Azabicyclo[4,3,0]nonan-4-yl)amino]-4-Bromo-phenylacetaldehyde, dimethyl acetal** ; from 2-Amino-4-bromo-phenylacetaldehyde, dimethyl acetal (500mg, 1.92mmol), 4-oxo-azabicyclo[4,3,0]nonane (2.88mmol), acetic acid (14ml) and NaBH(OAc)₃ (1.22g, 5.77mmol); yield 524.5mg (71%);

e) **4-Bromo-2-[(N-methyl-piperidin-4-yl)amino]-phenylacetaldehyde, dimethyl acetal** ; from 2-Amino-4-bromo-phenylacetaldehyde, dimethyl acetal (107 mg, 0.411mmol), N-methyl-4-piperidone (0.62mmol), acetic acid (3ml) and NaBH(OAc)₃ (261mg, 1.23mmol); yield 140.1mg (95%);

Example 10 : 6-Bromo-1-(tetrahydropyran-4-yl)-indole (compound 15).

4-Bromo-2-[(tetrahydropyran-4-yl)amino]-phenylacetaldehyde, dimethyl acetal (522mg, 1.516mmol) was dissolved in 20ml of 1M HCl in methanol. The solution was refluxed for 2hrs and the solvent evaporated to give the title compound (407mg, 96%) as an off-white solid.

In a similar fashion, the following compounds were prepared :

b) **6-Bromo-1-(tetrahydrothiopyran-4-yl)-indole** ; from 4-Bromo-2-[(tetrahydrothiopyran-4-yl)amino]-phenylacetaldehyde, dimethyl acetal (554.9mg, 1.52mmol). Yield 375mg (83%);

5 c) **6-Bromo-1-(4-piperidiny)-indole** ; from 4-Bromo-2-[(N-Butoxycarbonyl-piperidin-4-yl)amino]-phenylacetaldehyde, dimethyl acetal (728mg, 1.64mmol). Yield 349mg (76%);

d) **6-Bromo-1-(Azabicyclo[4,3,0]nonan-4-yl)-indole** ; from 2-[(Azabicyclo-
10 [4,3,0]-nonan-4-yl)amino]-4-Bromo-phenylacetaldehyde, dimethyl acetal (524 mg, 1.37mmoles). Products were separated by column chromatography on silica gel, eluting with 10% 2M ammonia/methanol in dichloromethane. Yield 236.7mg (54%) of the less polar isomer and 103.4mg (24%) of the more polar isomer ;

15

e) **6-Bromo-1-(N-methyl-piperidin-4-yl)-indole** ; from 4-Bromo-2-[(N-methyl-piperidin-4-yl)amino]-phenylacetaldehyde, dimethyl acetal (108mg, 0.30mmol). Yield 69.4mg (79%).

20 **Example 11 : 6-(2-Dimethylaminoethyl)-1-(tetrahydrothiopyran-4-yl)-indole (compound 17).**

6-Bromo-1-(tetrahydrothiopyran-4-yl)-indole (50mg, 0.169mmol), BINAP (12.5mg, 0.02mmol), Pd(DBA)₃ (7.7mg, 0.008mmol) and KHMDS (67mg, 0.338mmol) were mixed with 2ml of dioxane. N,N-dimethylacetamide (N,N-
25 DMA; 16mg, 0.186mmol) was added and the mixture heated to 100°C for 1 hr. After cooling slightly, the reaction mixture was diluted with dichloromethane and washed with water. The crude product was purified by column chromatography on silica gel, eluting with 5% 2M ammonia/methanol in dichloromethane to give 49.3mg of the amide intermediate, which was
30 dissolved in THF (3ml). A 1M solution of LiAlH₄ (0.34ml) was added, and the mixture refluxed for 2 hrs. The reaction was quenched with sodium sulphate decahydrate (Na₂SO₄·10H₂O), the mixture was filtered and the crude product

purified by column chromatography on silica gel, eluting with 5% 2M ammonia/methanol in dichloromethane to give the title compound (23mg, 47%) as a brown oil.

5 In a similar fashion, the following compounds were prepared :

b) 6-(2-Dimethylaminoethyl)-1-(tetrahydropyran-4-yl)-indole ;

6-Bromo-1-(tetrahydropyran-4-yl)-indole from (20mg, 0.071mmol), BINAP (3.3mg, 0.006mmol), Pd(DBA)₃ (3.25mg, 0.007mmol), KHMDS (28mg, 10 0.14mmol), N,N-DMA (18μl), 1M LiAlH₄ (0.14ml) and 2ml of THF. Yield (#mg, #%);

Example 12 : 6-Iodo-1H-indazole (compound 20).

Sodium nitrite (5.87g, 85mmol) in water (20mL) was added dropwise to an
15 ice-cooled solution of 6-aminoindazole (10g, 75.6mmol) in DMF (80mL) and hydrochloric acid (6M, 40mL). The mixture was stirred for 30 minutes. Potassium iodide (13.5g) was then added in small portions (gas evolution occurred) and the mixture stirred for 1h before warming to room temperature for 16h. The reaction was neutralized with aqueous sodium bisulfite, followed
20 by aqueous sodium hydroxide. The mixture was filtered to remove solids, and the solid was washed with water to remove impurities, and then with ethyl acetate and THF to collect the product. The organic washes were evaporated and recombined with the aqueous layer for extraction with ethyl acetate (3 x 250 mL). The organic layer was washed sequentially with water and brine,
25 dried over sodium sulfate, and the solvent removed *in vacuo*. Filtration chromatography on silica gel (35-60% ethyl acetate in hexane) gave a yellow solid which was triturated firstly with 50% ethyl acetate in hexane and then with ethyl acetate to yield the product (4.96g).

30 **Example 13 : 6-iodo-1-isopropyl-1H-indazole (compound 21).**

Sodium hydride (85mg, 60%, 2.12mmol) was added to an ice-cooled solution of 6-iodo-1H-indazole (249.5mg, 1.02mmol) in DMF (2.5mL). After stirring this

mixture for 1h at 0°C, 2-iodopropane (0.32mL, 3.2mmol) was added and the mixture stirred at 100°C for 16h. After the reaction mixture was partitioned between water and ethyl acetate, the organic layer was washed sequentially with water and brine, dried over sodium sulfate and the solvent removed *in vacuo*. Flash chromatography (silica gel, 5-20% ethyl acetate in hexane) yielded two products, the less polar 1-substituted-1H-indazole (105 mg) and the more polar 2-substituted indazolium (107.7 mg).

Example 14 : 6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-1H-indazole (compound 22).

A solution of 6-iodo-1-isopropyl-1H-indazole (49.6mg, 0.17mmol), tris-(dibenzylidenacetone)dipalladium(0) (8mg, 8.7µmol), S-BINAP (9mg, 15µmol), potassium bis(trimethylsilyl)amide (75mg, 0.37mmol) and N,N-dimethyl-acetamide (45µL, 0.48mmol) in 1,4-dioxane (2.5mL) was heated at 100°C for 2h. After cooling to room temperature, the reaction mixture was diluted with water (1mL) and passed through an EXTUBE using dichloromethane to elute (10mL). LiAlH₄ (0.4mL, 1M, 0.4mmol) was added to a solution of the crude product in THF (2.5mL) and the reaction mixture heated at reflux for 2h. After cooling to room temperature, the mixture was quenched with Rochelle's salt (1M, 1mL) and silica gel (to absorb water) and passed through a frit using methanolic ammonia in dichloromethane (0-10%). The 5% fraction was further purified by flash chromatography (silica gel, 2-8% methanolic ammonia in dichloromethane) to give the product (5.9 mg).

Example 15 : 6-[4-Hydroxy-azabicyclo[4,3,0]nonan-4-yl]-indole (compound 29).

To a suspension of potassium hydride (KH; 0.289g, 7.2mmol) in tetrahydrofuran (THF; 5ml) at -10°C was added, dropwise, a solution of 6-bromoindole (1.2g, 6mmol) in THF (1ml). The mixture was stirred at this temperature for 20mins, until no more evolution of hydrogen was observed. The mixture was then cooled to -78°C in an acetone/dry ice bath, 8.82ml of a 1.7M solution of ^tBuLi was added slowly, and the mixture stirred for another

30mins. Azabicyclo[4,3,0]nonan-4-one (1.67g, 1.2mmol) was then added, and the mixture stirred at -78°C for a further 30mins before being quenched with a mixture of dichloromethane (50ml) and pH7 buffer (50ml). After filtration, the organic layer was washed with water and brine, dried, concentrated, and the residue triturated with hexanes to give 0.52g of the title product as a white powder (33.1%).

b) In a similar fashion, **6-[4-Hydroxy-1-methyl-piperidin-4-yl]-indole** was prepared from 6-bromoindole (1.0g, 5mmol); KH (0.225g, 5.6mmol), 1.7M ^tBuLi (7.5ml, 12.7mmol) and N-methyl-4-piperidone (1.246g, 10.9mmol). Yield 0.382g (35%).

Example 16 : 6-[N-methyl-1,2,5,6-tetrahydropyridin-4-yl]-indole (compound 30).

The above compound (197mg, 0.855mmol) was mixed with THF (10ml) and trifluoroacetic acid (TFA; 1ml) and heated at 60-70°C until thin-layer chromatography (TLC) showed that the starting material had been consumed. The reaction mixture was quenched with silica gel and purified by column chromatography on silica gel (eluting with 2-5% of 2M ammonia/methanol in dichloromethane to give the title compound (173 mg, 95%).

In a similar fashion the following compounds were prepared :

b) **6-[3,4-anhydro-azabicyclo[4,3,0]nonan-4-yl]-indole** (yield 10.5mg, 56%) and **6-[4,5-anhydro-azabicyclo[4,3,0]nonan-4-yl]-indole** (yield 4.8mg, 26%); from 6-[4-Hydroxy-azabicyclo[4,3,0]nonan-4-yl]-indole (20mg, 0.078mmol) ;

c) **6-[N-Methyl-1,2,5,6-tetrahydropyridin-4-yl]-1-isopropyl-indole** : from 6-[4-Hydroxy-1-methyl-piperidin-4-yl]-1-isopropyl-indole (20mg, 0.0735mmol) in 0.1ml of TFA and 1ml of THF at 60-64°C. Yield 4.8 mg (26%).

Example 17 : 6-[Azabicyclo[4,3,0]nonan-4-yl]-indole (compound 31).

6-[3,4-anhydro-azabicyclo[4,3,0]nonan-4-yl]-indole (35mg, 0.147mmol) was stirred overnight under H₂, at room temperature, in the presence of 10%Pd/C (45mg) in ethanol. The reaction mixture was filtered through celite and concentrated *in vacuo* to give 35mg (99%) of the title product as a mixture of two diastereoisomers, which were separated by column chromatography on silica gel, eluting with 2% of 2M ammonia/methanol in dichloromethane.

Example 18 : 6-[3,4-Anhydro-azabicyclo[4,3,0]nonan-4-yl]-1-isopropyl-indole (compound 33, alkylation example).

A mixture of 6-[3,4-Anhydro-azabicyclo[4,3,0]nonan-4-yl]-indole (23.8mg, 0.1mmol), potassium carbonate (K₂CO₃; 27.6mg, 0.2mmol), sodium hydride (NaH; 4.8mg, 0.2mmol), dimethyl formamide (DMF; 0.1 ml) and 2-iodopropane (85mg, 0.5mmol) in 1 ml of toluene was heated to 90-100°C for 1hr. After cooling, dichloromethane was added and the mixture passed a silica gel column, eluting with 1% 2M ammonia/methanol in dichloromethane, to give the title compound (11.0mg, 39%) as a yellow oil.

Example 19 : 1-(4-Fluorophenyl)-6-(N-methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole (compound 32, arylation example).

A mixture of 6-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole (20.1mg, 0.0945mmol), potassium carbonate (K₂CO₃; 52.3mg, 0.3787mmol), cuprous bromide (CuBr; 6.7mg, 0.0473mmol), a little copper powder and 1-fluoro-4-iodobenzene (42.04mg, 0.189mmol) in 1ml of N-methyl-4-piperidone (NMP) was heated at 170°C, under argon, overnight. After cooling, the mixture was diluted with dichloromethane and the organic layer washed with water 10 times before being passed through a silica gel column (eluting with 1% 2M ammonia/methanol in dichloromethane) to give the title product (15mg, 55%).

In a similar fashion, the following compounds were prepared :

b) 6-[Azabicyclo[4,3,0]nonan-4-yl]-1-isopropyl-indole ; from 6-[Azabicyclo[4,3,0]nonan-4-yl]-indole (14mg, 0.05mmol), K₂CO₃ (16mg,

0.116mmol), NaH (4.8mg, 0.2mmol), DMF (0.1ml) and 2-iodopropane (30mg, 0.174mmol) in toluene (0.5ml) (yield 10.7mg (65%) as a yellow oil);

5 **c) 6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-thienyl)-indole** : from 6-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole (19.8mg, 0.0933mmol), K₂CO₃ (51.5mg, 0.373mmol), CuBr (6.7mg, 0.0466 mmol), a little Cu powder and 3-bromothiophene (30.4mg, 0.187mmol) in 1ml of NMP (yield 14.5mg, 53%);

10 **d) 6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-pyridyl)-indole** : from 6-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole (15mg, 0.0706mmol), K₂CO₃ (39mg, 0.283mmol), CuBr (5mg, 0.0353mmol), a little Cu powder and 3-bromopyridine (22.3mg, 0.141mmol) in 1ml of NMP (yield 11.5mg, 56%);

15 **e) 6-[Azabicyclo[4,3,0]nonan-4-yl]-1-(4-pyridinyl)-indole** : from 6-[Azabicyclo[4,3,0]nonan-4-yl]-indole (35mg, 0.145mmol), K₂CO₃ (80mg, 0.58mmol), CuBr (10.4 mg, 0.072mmol), a little Cu powder and 4-bromopyridine hydrochloride (71.4 mg, 0.29mmol) in 1ml of NMP. Yield : 10.3mg (22%) of the less polar isomer and 1.5 mg (8%) of the more polar isomer.

20 **f) 6-(2-Dimethylaminoethyl)-1-(3-pyridinyl)-indole**: from 6-(2-Dimethylaminoethyl)-indole (19.3mg, 0.102mmol), K₂CO₃ (56.6mg, 0.41mmol), CuBr (7.3mg, 0.0353mmol), a little Cu powder and 3-bromopyridine (32.4mg, 0.205mmol) in 1ml of NMP (yield 8mg , 29 %);

25 **g) 6-(2-Dimethylaminoethyl)-1-(3-thienyl)-indole**: from 6-(2-Dimethylaminoethyl)-indole (17.6mg, 0.093mmol), K₂CO₃ (51.6mg, 0.374mmoles), CuBr (6.7mg, 0.0467mmol), a little Cu powder and 3-bromothiophene (30.5mg, 0.187mmol) in 1ml of NMP (yield 2mg, 8%).

30 **h) 6-(2-Dimethylaminoethyl)-1-(4-fluorophenyl)-indole** : from 6-(2-Dimethyl-aminoethyl)-indole (18.5mg, 0.098mmol), K₂CO₃ (54.2mg,

0.393mmol), CuBr (7mg, 0.049mmol), a little Cu powder and 1-fluoro-4-iodobenzene (43.6mg, 0.196mmol) in 1ml of NMP (yield 12.7mg, 46%);

- 5 i) **6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(2-thiazolyl)-indole** : from 6-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole (15.2mg, 0.0715mmol), K_2CO_3 (39.5mg, 0.283mmol), CuBr (5.1mg, 0.0357mmol), a little Cu powder and 2-bromothiazole (23.5mg, 0.143mmol) in 1ml of NMP (yield 8.6mg, 41%);

10 **Example 20 : 1-Dimethylaminocarbonyl-6-[N-methyl-1,2,5,6-tetrahydropyridin-4-yl]-indole (compound 33, amidation example).**

From 6-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole (16.6mg, 0.0735mmol), dimethylcarbonyl chloride (15.8mg, 0.147mmol) and 1M $NaN(TMS)_2$ (0.147ml) in 0.5ml of THF at 0°C. Yield 12.5 mg (60 %), the reaction being carried out according to Example 6.

15

Example 21 : 6-bromo-1-isopropylindole (compound 34).

- A mixture of 6-bromoindole (2.0g, 10mmol), K_2CO_3 (2.76g, 20mmol), NaH (0.48g, 20mmol), DMF (1 ml) and 2-iodopropane (8.5g, 50mmol) in 40 ml of toluene was heated at 90~100°C for 2hr. The reaction mixture was diluted
20 with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate (Na_2SO_4), concentrated *in vacuo* and the residue purified by column chromatography on silica gel, eluting with hexanes, to give (2.32g, 97%) of the title product.

25 **Example 22 : 6-[4-Hydroxy-1-methyl-piperidin-4-yl]-1-isopropyl-indole (compound 35).**

- 1.5ml of a solution of 6-bromo-1-isopropylindole (240mg, 1mmol) was cooled to -78 °C, 1.7M $tBuLi$ (1.47ml, 2.5mmol) was added and the mixture stirred for 7mins. N-Methyl-4-piperidone (340.8mg, 3mmol) was then added and the
30 mixture stirred for a further 10mins. The reaction mixture was then warmed up to -20°C and quenched with water and dichloromethane. The organic layer was washed with water, dried over anhydrous Na_2SO_4 , concentrated *in vacuo*

and the residue purified by column chromatography on silica gel, eluting with 2% 2M ammonia/methanol in dichloromethane to give the title product (120mg, 44%).

5 **Example 23 : 6-((N-Benzyloxycarbonyl)prolyl)-indole** (compound 39)

To a suspension of KH (14 mg, 7.2mmol) in 1 ml of THF, 6-bromoindole (600mg, 6mmol) in 1ml of THF was added, dropwise at -10°C, and the mixture stirred at this temperature for about 20mins, until no more hydrogen evolution was observed. The reaction mixture was cooled to -78°C, 1M ^tBuLi
10 (4.4 ml, 7.5mmol) was added slowly, and stirring continued for another 30 mins. L-Cbz-proline methylester (1.5g, 6 mmol) was then added and the mixture stirred for a further 30mins, before being quenched with a mixture of dichloromethane (25ml) and pH7 buffer (25ml). The solids were filtered off and the organic layer washed with water and brine, dried and concentrated *in*
15 *vacuo*. Purification by flash chromatography, using 20% EtOAc/Hexanes as eluant, gave 184mg (17%) of the title compound.

Example 24 : 6-[(α -Hydroxy- α -(2-Pyrrolidinyl))methyl]-indole and 6-((2-Pyrrolidinyl)methyl)-indole (Compounds 38 & 40).

20 To a stirred solution of the 6-((N-Benzyloxycarbonyl)prolyl)-indole (35mg, 0.1mmol) in 1ml of THF, was added, dropwise at 0 °C, 1 ml of 1M LiAlH₄ in THF. The reaction mixture was refluxed overnight. After cooling to room temperature, the reaction was quenched Na₂SO₄ 10H₂O, filtered and the crude product purified by chromatography on silica gel, eluting with 10% 2M
25 ammonia/methanol in dichloromethane to give a mixture of 6-[(α -Hydroxy- α -(2-Pyrrolidinyl))methyl]-indole and 6-((2-Pyrrolidinyl)methyl)-indole, (10.4mg, 45%) and (6.8mg, 30%), respectively.

Example 25 : 6-Bromo-1-triisopropylsilyl-indole (compound 42).

30 A solution of 6-Bromoindole (1g, 5mmol) in DMF (3ml) was added to a suspension of NaH (134.7mg, 5.6mmol) in DMF (98ml) at 0°C and stirred for 15mins. Triisopropylsilyl chloride (1.082g, 5.6mmol) was added dropwise, and

the reaction mixture stirred for 2h before being poured into ice-water and extracted with ethyl acetate. The organic layer was washed with brine, concentrated *in vacuo* and the crude product passed through a silica gel column, eluting with hexanes, to give the title compound (406.7 mg, 23%) as a colourless oil.

Example 26 : 6-(3-methylpiperazinyl)-1-triisopropylsilyl-indole (compound 43).

From 6-Bromo-1-triisopropylsilyl-indole (400mg, 1.14mmol), 2-methylpiperazine (1.36mg, 13.6mmol), NaO^tBu (0.153mg, 1.59mmol), ^tBu₃P (12mg) and Pd(OAc)₂ (3mg) in xylene (1ml) under argon. The reaction mixture was heated to 120°C (59%).

Example 27 : 6-(N-methylpiperazinyl)-indole (compound 44).

To a solution of 6-(N-methylpiperazinyl)-1-triisopropylsilyl indole (237mg, 0.64mmol) in 1 ml of THF, 1M TBAF (0.64 ml, 0.64mmol) was added dropwise at room temperature. After 30 mins, the mixture was diluted with dichloromethane and washed 3 times with water to give the title product (100.6 mg, 73% yield).

Example 28 : 1-Isopropyl-6-(N-methylpiperazinyl)-indole (compound 45, from compound 46).

A mixture of 6-bromo-1-isopropylindole (23.8mg, 0.1mmol), sodium-^tbutoxide (NaO^tBu; 14.1mg, 0.15mmol), tri-^tbutyl phosphine (^tBu₃P; 1mg), palladium acetylacetonate (Pd(OAc)₂; 1mg) and 1-methylpiperazine (60mg, 0.6mmol) in xylene (1ml) under argon was heated at 120°C for 3h., The cooled reaction mixture was diluted with dichloromethane, washed with water and the crude product purified by column chromatography on silica gel, eluting with 1% 2M ammonia/methanol in dichloromethane to give (11.3mg, 44%) of the title compound.

In a similar fashion, the following compounds were prepared :-

b) **1-Isopropyl-6-(N-methylhomopiperazinyl)-indole** ; from 6-bromo-1-isopropyl-indole (23.8mg, 0.1mmol), 1-methylhomopiperazine (68.4mg, 0.6mmol), NaO^tBu (14.1mg, 0.15mmol), ^tBu₃P (1mg) and Pd(OAc)₂ (1mg) in
5 xylene (1ml), heating overnight. Yield 8.3mg (31%);

c) **6-(1,3-Diazabicyclo-[4,4,0]-decan-3-yl)-1-isopropyl-indole** ; from 6-bromo-1-isopropylindole (23.8mg, 0.1mmol), 1,3-Diazabicyclo-[4,4,0]-decane (75.6mg, 0.6mmol), NaO^tBu (14.1mg, 0.15mmol), ^tBu₃P (1mg) and Pd(OAc)₂
10 (1mg) in xylene (1ml), heating overnight. Yield 9.4mg (32%);

d) **1-Isopropyl-6-(3-methylpiperazinyl)-indole** ; from 6-Bromo-1-isopropylindole (23.8mg, 0.1mmol), 2-methylpiperazine (60mg, 0.6mmol), NaO^tBu (14.1mg, 0.15mmol), ^tBu₃P(1mg) and Pd(OAc)₂(1mg) in xylene (1ml),
15 heating overnight. Yield 6.7mg (26%).

Example 29 : 1-Isopropyl-6-(4-methylpiperazinyl)-indole (compound 45, from compound 44, alkylation example).

A mixture of 6-(4-methylpiperazinyl)-indole (8.3mg, 0.386mmol), K₂CO₃
20 (21mg, 0.154mmol), NaH (3mg, 0.125mmol), DMF (0.1 ml) and 2-iodopropane (26.3μl, 0.154mmol) in 0.5 ml of toluene was heated to 90-100°C for 1hr. After cooling, dichloromethane was added and the mixture passed a silica gel column, eluting with 1% 2M ammonia/methanol in dichloromethane, to give the title compound (8.2mg, 83% yield).

25

Example 30 : 1-(4-Fluorophenyl)-6-(4-methylpiperazinyl)-indole (compound 45, from compound 44, arylation example).

A mixture of 6-(4-Methylpiperazinyl)-indole (14.8mg, 0.0687mmol), K₂CO₃
(37.9mg, 0.275mmol), CuBr (4.9mg, 0.0353mmol), a little copper powder and
30 1-Fluoro-4-iodobenzene (30.5mg, 0.37mmol) in 1ml of NMP was heated at 170°C, under argon, overnight. After cooling, the mixture was diluted with dichloromethane and the organic layer washed with water 10 times before

being passed through a silica gel column (eluting with 1% 2M ammonia/methanol in dichloromethane) to give the title product (7.8mg, 37%).

In a similar fashion, the following compounds were prepared :

- 5 **b) 6-(4-methylpiperazinyl)-1-(3-thiazolyl)-indole** ; from 6-(4-Methylpiperazinyl)-indole (15.4mg, 0.0715mmol), K₂CO₃ (39.5mg, 0.286mmol), CuBr (5.1mg, 0.0357mmol), Cu powder (a little) and 3-Bromotiazole (23.4mg, 0.143mmol) in 1ml of NMP. Yield 1.7mg (8%) ;
- 10 **c) 6-(4-methylpiperazinyl)-1-(3-thienyl)-indole** ; from 6-(4-Methylpiperazinyl)-indole (15.1mg, 0.0701mmol), K₂CO₃ (38.7mg, 0.28mmol), CuBr (5mg, 0.0353mmol), Cu powder (a little) and 3-bromothiophene (22.9mg, 0.14mmol) in 1 ml of NMP. Yield 1.2mg (6%).

15 **Example 31**

(a) *tert*-Butyl 2-(1-(2-propyl)-1H-indazol-6-yl)acetate:

- Ethyl magnesium bromide (1M in THF, 0.10 mL, 0.10 mmol) was added to a suspension of NiCl₂(PPh₃)₂ (17.2 mg, 0.026 mmol) and PPh₃ (13.9 mg, 0.053 mmol) in diethyl ether (0.5 mL). The resulting catalyst solution was stirred for
- 20 10-15 min at room temperature under an atmosphere of argon. A solution of 6-iodo-1-(2-propyl)-1H-indazole (73 mg, 0.26 mmol) in diethyl ether (1.5 mL) was added to this pre-formed catalyst mixture, followed by a solution of 2-*tert*-butoxy-2-oxoethylzinc chloride (from Rieke Metals Inc, 0.5M in diethyl ether, 1.0 mL, 0.5 mmol) and finally 1-methyl 2-pyrrolidinone (1.0 mL). The resulting
- 25 mixture formed a dark red homogeneous solution that was heated at 45 °C for 15 h. After cooling to room temperature, the reaction mixture was partitioned between ethyl acetate (75 mL) and half-saturated brine (25 mL). The organic layer was washed with brine (5x 25 mL) and dried over anhydrous sodium sulfate. After removal of the solvent *in vacuo*, flash chromatography (silica
- 30 gel, 5-10% ethyl acetate in hexane) yielded pure *tert*-butyl 2-(1-(2-propyl)-1H-indazol-6-yl)acetate (48.6 mg, 66%).

(b) 6-(2-(N,N-Diethylamino)ethyl)-1-(2-propyl)-1H-indazole:

DIBAL-H (0.69 mL, 1.5 M, 1.03 mmol) in toluene was added at 0 °C to a solution of *tert*-butyl 2-(1-(2-propyl)-1H-indazol-6-yl)acetate (48 mg, 0.18 mmol) in tetrahydrofuran (2 mL). After stirring at 0 °C for 15 min, the ice bath was removed and the reaction mixture was stirred for 2 h at room

5 temperature, and quenched with sodium sulfate decahydrate. The product was taken into ethyl acetate, filtered to remove the solid residue, and the solvent was removed *in vacuo* to yield the crude alcohol that was used without further purification.

Methanesulfonyl chloride (18 µL, 0.23 mmol) was added to an ice-cooled
10 solution of the crude alcohol and triethylamine (60 µL, 0.42 mmol) in dichloromethane (1.5 mL). After stirring at 0 °C for 1 h, the reaction was quenched by dilution with dichloromethane and washing sequentially with sodium hydrogen sulfate (aqueous, 1M), sodium bicarbonate (aqueous, saturated) and brine. The organic layer was dried over anhydrous sodium
15 sulfate and the solvent was removed *in vacuo* yielding the crude mesylate. Diethylamine (0.20 mL, 1.9 mmol) was added to a solution consisting of one-half of the crude 2-(1-(2-propyl)-1H-indazol-6-yl)ethyl methanesulfonate in THF (1.0 mL) and the resulting mixture was gently refluxed for 12 h. After cooling to room temperature, the solvent was removed *in vacuo*, sodium
20 hydroxide (1M, aqueous, 0.8 mL) was added, and the mixture was passed through an EXTUBE (VARIAN, 3 mL tube, diatomaceous earth) and extracted into dichloromethane (15 mL). After evaporation of the solvent, flash chromatography (silica gel, 0 - 5% 2M methanolic ammonia in dichloromethane) yielded the product (7.0 mg, 31%).

25

In a like manner, the following compounds were prepared:

(C) 6-(2-(N-pyrrolidinyl)ethyl)-1-(2-propyl)-1H-indazole: (11.2 mg, 50%); from
2-(1-(2-propyl)-1H-indazol-6-yl)ethan-2-ol via the methanesulfonate (0.088
30 mmol) and pyrrolidine (0.16 mL, 1.9 mmol).


- (d) **6-(2-(N-pyrrolin-3-yl)ethyl)-1-(2-propyl)-1H-indazole:** (14.7 mg, 60%); from 2-(1-(2-propyl)-1H-indazol-6-yl)ethan-2-ol via the methanesulfonate (0.096 mmol) and 3-pyrroline (200 mg, 2.9 mmol).
- 5 (e) **(R)-6-(2-(N-(3-tert-butoxycarbonylamino)pyrrolidinyl)ethyl)-1-(2-propyl)-1H-indazole:** (36.0 mg, 88%); from 2-(1-(2-propyl)-1H-indazol-6-yl)ethan-2-ol via the methanesulfonate (0.11 mmol) and (R)-3-tert-butoxycarbonylamino)pyrrolidine (51 mg, 0.27 mmol).
- 10 (f) **(S)-6-(2-(N-(3-tert-butoxycarbonylamino)pyrrolidinyl)ethyl)-1-(2-propyl)-1H-indazole:** (37.6 mg, 92%); from 2-(1-(2-propyl)-1H-indazol-6-yl)ethan-2-ol via the methanesulfonate (0.11 mmol) and (S)-3-tert-butoxycarbonylamino)pyrrolidine (51 mg, 0.27 mmol).
- 15 (g) **(R)-6-(2-(N-(2-hydroxymethyl)pyrrolidinyl)ethyl)-1-(2-propyl)-1H-indazole:** (30.5 mg, 98%); from 2-(1-(2-propyl)-1H-indazol-6-yl)ethan-2-ol via the methanesulfonate (0.11 mmol) and (R)-pyrrolidine-2-methanol (29 mg, 0.29 mmol).
- 20 (h) **(S)-6-(2-(N-(2-hydroxymethyl)pyrrolidinyl)ethyl)-1-(2-propyl)-1H-indazole:** (30.3 mg, 98%); from 2-(1-(2-propyl)-1H-indazol-6-yl)ethan-2-ol via the methanesulfonate (0.11 mmol) and (S)-pyrrolidine-2-methanol (29 mg, 0.29 mmol).
- 25 (i) **6-(2-(N-cyclopropylamino)ethyl)-1-(2-propyl)-1H-indazole:** (16.5 mg, 62%); from 2-(1-(2-propyl)-1H-indazol-6-yl)ethan-2-ol via the methanesulfonate (0.11 mmol) and cyclopropylamine (0.22 mL, 3.2 mmol).
- 30 (j) **6-(2-(N-cyclopropylmethylamino)ethyl)-1-(2-propyl)-1H-indazole:** (14.7 mg, 54%); from 2-(1-(2-propyl)-1H-indazol-6-yl)ethan-2-ol via the methanesulfonate (0.10 mmol) and cyclopropylmethylamine (0.27 mL, 3.1 mmol).

(k) **6-(2-(N-methylpiperazino)ethyl)-1-(2-propyl)-1H-indazole:** (20.0 mg, 84%); from 2-(1-(2-propyl)-1H-indazol-6-yl)ethan-2-ol via the methanesulfonate (0.083 mmol) and N-methylpiperazine (0.18 mL, 1.6 mmol).

5

Example 32

From the reaction schemes set out below, the following further compounds were prepared:



i. 2-iodopropane, NaN(TMS)₂ or NaH, DMF, 60 °C; ii. 1-BuLi, (L)-N-CBZ-proline, THF, -78 °C; iii. a) MeSi, Et₃N, CH₂Cl₂, b) LiAlH₄, THF, reflux; iv. 1-BuLi, 5-(S)-(3,3,0)-1-axa-2-thia-3-oxabicyclooctane-2,2-dioxide, THF, v. TIPSCl, NaN(TMS)₂, THF, vi. as in: vii. a) MeSi, Et₃N, CH₂Cl₂, b) LiAlH₄, THF, reflux; c) 1) Bu₄NF, THF; ii) Ar-X, CuBr, Cu, NMP, 170 °C; ix. PhSeO₂Cl, NaN(TMS)₂, THF; x. cyclic alcohol, NaH, K₂CO₃, toluene, 100 °C; xi. a) NaBH₃CO₃, HOAc; b) cyclic ketone, etc.; Pd/C or Raney Ni, n-propane, 100 °C.

(a) N,N-diethyl-2-(1-benzenesulfonyl-1H-indol-6-yl)ethanamine

To the solution of 2-(1*H*-indol-6-yl)-*N,N*-dimethylethanamine (50 mg, 0.231 mmol) and 1 M NaN(TMS)₂ (0.462 ml, 0.462 mmol) with THF (1.5 mL), benzenesulfonyl chloride (82 mg, 0.462 mmol) was added. After 1 hour, the mixture was diluted with dichloromethane and purified with column chromatography with 1% methanol (2M NH₃) in dichloromethane to give 42.3 mg, yield: 51%.

(b) N,N-diethyl-2-(1-tetrahydro-2H-pyran-4-yl-1H-indol-6-yl)ethanamine

N,N-diethyl-2-(1-benzenesulfonyl-1H-indol-6-yl)ethanamine (38 mg, 0.1066 mmoles) was mixed with NaH(60%, 20.5 mg, 0.5330mmoles),potassium carbonate (44 mg, 0.3198mmoles) and tetrahydro-2H-4-pyranol (0.0406 ml) in
5 toluene at 0°C. The mixture was heated to 110 °C overnight. The product was purified by column with 1~2% methanol(2M NH₃) in dichloromethane to give 5.7 mg, yield: 18%

c) N,N-diethyl-2-[1-(4-fluorophenyl)-1H-indol-6-yl]ethanamine (11.4 mg ,

10 53 %); from 2-(1H-indol-6-yl)-N,N-diethylethanamine (15.9 mg, 0.0735 mmoles), K₂CO₃ (40.5 mg, 0.294mmoles), CuBr (5.3 mg, 0.0368 mmoles), Cu powder (a little) and 4-fluoro-iodobenzene(32.6 mg, 0.147 mmoles) in 1 ml of NMP

(d) N,N-diethyl-2-[1-(3-thienyl)-1H-indol-6-yl]ethanamine (2.6 mg , 10 %);

15 from 2-(1H-indol-6-yl)-N,N-diethylethanamine (19.4 mg, 0.0897 mmoles), K₂CO₃ (49.5 mg, 0.3587mmoles), CuBr (6.4 mg, 0.0448 mmoles), Cu powder (a little) and 3-bromothiophene(29.2 mg, 0.179 mmoles) in 1 ml of NMP

20

(e) tert-butyl(2S)-2-[hydroxy(1-isopropyl-1H-indol-6-yl)methyl]pyrrolidine-1-carboxylate

tert-butyl(2S)-2-[hydroxy(1-isopropyl-1H-indol-6-yl)methyl]pyrrolidine-1-
25 carboxylate (3.65 g, 40.4 %); from 6-bromo-1-isopropylindole(6.0 g, 25.2 mmolesmmoles) in THF (10ml)at -10 °C, treated with 1.7 M t-BuLi(27.5ml, 46.75 mmoles) and (L)-N-CBZ-proline(4.67g, 23.4 mmoles) at -78 °C.

(f) tert-butyl (2S)-2-[hydroxy(triisopropylsilyl-1H-indol-6-yl)methyl]pyrrolidine-1-carboxylate

30 tert-butyl (2S)-2-[hydroxy(triisopropylsilyl-1H-indol-6-yl)methyl]pyrrolidine-1-carboxylate (850 mg, 63.2%); from 6-bromo-1-triisopropylsilyl-indole (1000mg,

2.8 mmoles) treated with 1.7 M t-BuLi (3.62 ml, 6.16 mmoles) and reacted with and (L)-N-CBZ-proline(0.565 g, 2.8 mmoles) at -78 °C.

(g) 1-isopropyl-6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1H-indole

- 5 To the dichloromethane (20 ml) solution of tert-butyl(2S)-2-[hydroxy(1-isopropyl-1H-indol-6-yl)methyl] pyrrolidine-1-carboxylate (1.075g, 3 mmoles) and Et3N(1.21g, 12 ml), methanesulfonyl chloride was added dropwise at 0~5 °C. One hour later the mixture was washed with brine and dried with NaSO4, concentrated, then mixed with 30 ml of 1M LiAlH4 at r.t. carefully. After the
10 reaction mixture was heated to reflux for 2 hours, NaSO4·10H2O was used to quench the excess of LiAlH4. The reaction mixture was diluted with ethyl acetate, filtered purified with column chromatography with 2% methanol(2 M NH3) in dichloromethane to give 685 mg of product, yield:89%

- 15 **(h) 1- triisopropylsilyl-6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1H-indole**
1- triisopropylsilyl-6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1H-indole(450 mg, 73.4 %); from tert-butyl (2S)-2-[hydroxy(triisopropylsilyl-1H-indol-6-yl)methyl]pyrrolidine-1-carboxylate (794 mg, 1.68 mmoles) reacted with methanesulfonyl chloride(230 mg, 2.0 mmoles) in Et3N(509 mg, 5.04
20 mmoles) and 10 ml of dichloromethane, followed by treated with 1 M LiAlH4(16.8 ml, 16.8 mmoles)

- (i) 6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1H-indole** (179 mg, 68.8%);
from 1- triisopropylsilyl-6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1H-indole (450
25 mg, 1.214 mmoles)with 1M Bu4NF(1.6 mmoles) and 1 ml of THF

- (j) 6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1-(3-thienyl)-1H-indole** (4.2mg, 30.4%); from 6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1H-indole (10 mg, 0.0466 mmoles), K2CO3 (24.7 mg, 0.179mmoles), CuBr (3.2 mg, 0.0224
30 mmoles), Cu powder (a little) and 3-bromothiophene(20 mg, 0.123 mmoles) in 0.5 ml of NMP

(k) **1-(4-fluorophenyl)-6-([(2S)-1-methylpyrrolidin-2-yl]methyl)-1H-indole** (5.8 mg, 53 %); from 6-([(2S)-1-methylpyrrolidin-2-yl]methyl)-1H-indole (10 mg, 0.0466 mmol), K₂CO₃ (24.7 mg, 0.179 mmol), CuBr (3.2 mg, 0.0224 mmol), Cu powder (a little) and 4-fluoroiodobenzene (27.3 mg, 0.123 mmol) in 0.5 ml of NMP

(l) **1-(pyridin-3-yl)-6-([(2S)-1-methylpyrrolidin-2-yl]methyl)-1H-indole** (1.6 mg, 11.8 %); from 6-([(2S)-1-methylpyrrolidin-2-yl]methyl)-1H-indole (10 mg, 0.0466 mmol), K₂CO₃ (24.7 mg, 0.179 mmol), CuBr (3.2 mg, 0.0224 mmol), Cu powder (a little) and 3-bromopyridine (19.4 mg, 0.123 mmol) in 0.5 ml of NMP

(m) **1-(pyridin-4-yl)-6-([(2S)-1-methylpyrrolidin-2-yl]methyl)-1H-indole** (1.6 mg, 11.8 %); from 6-([(2S)-1-methylpyrrolidin-2-yl]methyl)-1H-indole (10 mg, 0.0466 mmol), K₂CO₃ (49.5 mg, 0.3587 mmol), CuBr (3.2 mg, 0.0224 mmol), Cu powder (a little) and 4-bromopyridine hydrochloride (16.1 mg, 0.0823 mmol) in 0.5 ml of NMP

(n) **1-propyl-6-([(2S)-methyl-pyrrolidin-2-yl]methyl)-1H-indole**
6-([(2S)-1-methylpyrrolidin-2-yl]methyl)-1H-indole (10 mg, 0.0467 mmol) was mixed with 1M NaN(TMS)₂ (0.094 ml, 0.094 mmol) in 0.5 ml of THF, then iodopropyl (32.7 mg, 0.1867 mmol) was added at r.t. and the reaction was stirred overnight. The product was purified with column chromatography with 1% methanol (2M NH₃) in dichloromethane to give 3.8 mg, yield: 31.6%

(o) **1-dodecyl-6-([(2S)-methyl-pyrrolidin-2-yl]methyl)-1H-indole** (6.8 mg, 38.1%); from 6-([(2S)-1-methylpyrrolidin-2-yl]methyl)-1H-indole (10 mg, 0.0467 mmol) reacted with iodododecane (55.3 mg, 0.1867 mmol) and 1M NaN(TMS)₂ (0.094 ml, 0.094 mmol) in 0.5 ml of THF at r.t. overnight.

(p) **1-isopropyl-6-(1-methylpiperidin-3-yl)-1H-indole**

6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1*H*-indole(10 mg, 0.0467 mmoles) was mixed with NaH(2.2 mg,0.0933mmoles), K₂CO₃(25 mg, 0.1866 mmoles)and 2-iodopropane(31.7 mg, 0.01866 mmoles) in toluene and heated to 100~110 °C for 2 hours. The reaction mixture was cooled down and diluted with dichloromethane. The product was purified with column chromatography with 1.5% methanol(2M NH₃) in dichloromethane to give 1-isopropyl-6-(1-methylpiperidin-3-yl)-1*H*-indole 4.6mg, yield:38.5%. The expected compound 1-isopropyl-6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1*H*-indole was not obtained.

10

(q)1-benzenesulfonyl-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl-1*H*-indole

(106 mg, 98.6%); from 6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl-1*H*-indole(65 mg, 0.3037 mmoles) reacted with benzenesulfonylchloride(106.9 mg, 0.607 mmoles) and 1M NaN(TMS)₂(0.607 ml, 0.607 mmoles) in THF(3 ml) at r.t.

15

(r)1-(tetrahydro-2*H*-thiopyran-4-yl)-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl-1*H*-indole (5.8 mg, 10%); from 1-benzenesulfonyl-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl-1*H*-indole(65 mg, 0.183mmoles)reacted with tetrahydro-2*H*-thiopyran-4-ol(108 mg, 0.915 mmoles) with NaH(17.5 mg, 0.729 mmoles),and K₂CO₃(50.5 mg, 0.366 mmoles) in toluene.

20

(s) 6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl -1-(tetrahydro-2*H*-pyran-4-yl)indoline and 6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl-1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-indole

25

6-[[*(2S)*-1-methylpyrrolidin-2-yl]methyl]-1*H*-indole(21.4 mg, 0.1 mmoles) was mixed with acetic acid(0.4 ml) at 15 °C, then NaBH₃CN(12.56 mg, 0.2 mmoles) was added in portions. After half of an hour , tetrahydro-4*H*-pyran-4-one (20 mg, 0.2 mmoles) was added and stirred for 3 hours. The reaction mixture was basified to pH 10~11 with 1M KOH extrated with dichloromethane to give 6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl -1-(tetrahydro-2*H*-pyran-4-yl)indoline. This compound was mixed with 50 mg of 10% Pd/C

30

and 1 ml of n-propanol and heated to 100 °C for 0.5 hour until no indoline compound left, passed the column with 1.5 % methanol (2M NH₃) in dichloromethane to give 3.5mg of 1-(tetrahydro-2H-pyran-4-yl)-6-{[(2S)-methyl-pyrrolidin-2-yl]methyl}-1*H*-indole, yield:11.7%

5

(t)1-(1-methylpiperidin-4-yl) 6-{[(2S)-methyl-pyrrolidin-2-yl]methyl indoline(21.1mg, 64.2 %); from 6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1*H*-indole(21.4 mg, 0.1 mmoles) reacted with NaBH₃CN(18.84mg, 0.3 mmoles) in acetic acid , followed by being treated with N-methyl-4-piperinone(22.6 mg, 0.2 mmoles)

10

(u)1-(1-methylpiperidin-4-yl) 6-{[(2S)-methyl-pyrrolidin-2-yl]methyl indole (6.9 mg, 34.8%); from 1-(1-methylpiperidin-4-yl) 6-{[(2S)-methyl-pyrrolidin-2-yl]methyl indoline(20.1 mg, 0.0642 mmoles) with Raney Ni (43 mg) in n-propanol(0.5 ml) at 100 ~110 °C

15

(v) 1-(1-benzylpiperidin-4-yl) 6-{[(2S)-methyl-pyrrolidin-2-yl]methyl indoline (24mg, 61.6%); from 6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1*H*-indole(21.4 mg, 0.1 mmoles) reacted with NaBH₃CN(18.84mg, 0.3 mmoles) in acetic acid , followed by being treated with N-benzyl-4-piperinone(37.8 mg, 0.2 mmoles)

20

(w) 1-(1-propylpiperidin-4-yl) 6-{[(2S)-methyl-pyrrolidin-2-yl]methyl indole (2.3 mg, 11%); from 1-(1-benzylpiperidin-4-yl) 6-{[(2S)-methyl-pyrrolidin-2-yl]methyl indoline(24 mg, 0.0616 mmoles) with Raney Ni (50 mg) in n-propanol (0.5 ml) at 100 ~110 °C The expected compound 1-(1-benzylpiperidin-4-yl) 6-{[(2S)-methyl-pyrrolidin-2-yl]methyl indole was not obtained

25

(x)1-cyclohexyl-6-{[(2S)-methyl-pyrrolidin-2-yl]methyl indoline(25mg, 83.9%); from 6-{[(2S)-1-methylpyrrolidin-2-yl]methyl}-1*H*-indole(21.4 mg, 0.1

30

mmoles) reacted with NaBH₃CN(18.84mg, 0.3 mmoles) in acetic acid , followed by being treated with cyclohexanone(19.6 mg, 0.2 mmoles).

- 5 (y) **1-cyclohexyl-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl indole** (5.1 mg, 20.6%); from cyclohexyl-6-[[*(2S)*-methyl-pyrrolidin-2-yl]methyl indoline(25 mg, 0.0837 mmoles) with Raney Ni (41 mg) in n-propanol (0.5 ml) at 100 ~110 °C

(z)1-isopropyl-6-[[*(2S)*-pyrrolidin-2-yl]methyl]-1*H*-indole

- 10 To the THF(25 ml) solution of 6-bromoindole(4.4 g, 18.5 mmoles), 1.7M t-BuLi (24 ml, 40.7 mmoles) was added dropwise at –78 °C under argon for 1 hour. After the mixture was stirred for another half of hour, 5-(*S*)-[3.3.0]-1-aza-2-thia-3-oxabicyclooctane-2,2-dioxide (2.4 g, 16.6 mmoles) in 5 ml of THF was added at –78 °C. Then the reaction mixture was warmed to r.t . naturally,
- 15 poured into saturated NH₄Cl and extracted with dichloromethane. The dichloromethane layer was washed with water and brine, dried with Na₂SO₄, concentrated, triturated with hexanes to give 1.6 g of sulfamic acid intermediate. This intermediate was mixed with 2M HCl (16 ml) and ethanol (16 ml) and heated to reflux overnight. The reaction solution was cooled
- 20 down, basified to pH 9~10 with K₂CO₃, extracted with dichloromethane. Dichloromethane layer was washed with brine and dried with Na₂SO₄, purified with column chromatography with 2% methanol(2M NH₃) in dichloromethane to give 340 mg of product, yield: 7.6 %

- 25 **(aa)1-isopropyl-6-(1-methylpiperidin-4-yl)-1*H*-indole** (6 mg, 21 %); from 6-(1-methylpiperidin-4-yl)-1*H*-indole(26 mg, 0.1213 mmoles) reacted with 2-iodopropane (71.35 mg, 0.3639 mmoles) , K₂CO₃(38.6 mg, 0.2426 mmoles) and NaH(22mg, 0.917 mmoles)in toluene(1.8 ml) and DMF(0.2 ml) at 100 °C

- 30 **(bb)1-benzyl-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1*H*-indole**(5.1 mg, 22%); from 6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1*H*-indole(16 mg,

0.0753mmoles) reacted with benzyl bromide(19.3 mg, 0.113 mmoles) and 1M NaN(TMS)₂ (0.113 ml, 0.113 mmoles) in THF(1 ml)

Example 33 : Comparison of the Binding Affinities.

- 5 Selected compounds of the previous examples, as well as reference compounds, were evaluated for binding affinity using cell types receptive specifically to 5-HT_{1D} and 5-HT_{1B} ligands. The assay protocol generally entailed the incubation of membranes prepared from cells expressing the 5-HT_{1D} or
- 10 5-HT_{1B} subtype of 5-HT receptors with ³H-serotonin (1 nM for 5-HT_{1D} and 2.5 nM for 5-HT_{1B}). Specific concentrations of the test compound were incubated with the radioligand and the membrane homogenates prepared from the recombinant cells. After a 60 minute incubation at 22 °C, the incubation was terminated by vacuum filtration. The filters were washed with buffer and
- 15 counted for radioactivity using liquid scintillation spectroscopy. The affinity of the test compound for the 5-HT_{1D} receptor is expressed as the amount (in percent) of binding of the radioligand that is inhibited in the presence of 100 nM of test compound. A greater percent inhibition indicates greater affinity for the 5-HT_{1D} receptor. Preferred compounds of the invention showed a percent
- 20 inhibition of greater than 50% at the 5-HT_{1D} receptor (such as those of examples 10c, 16c and 19i). More preferred compounds of the invention showed a percent inhibition of greater than 75% at the 5-HT_{1D} receptor (such as those of examples 19, 19c, 19d and 30a,). Most preferred compounds of the invention showed a percent inhibition of greater than 90% at the 5-HT_{1D}
- 25 receptor (such as those of examples 2, 11b, 14, 19f and 19g). In terms of selectivity, preferred compounds of the invention having a percent inhibition of greater than 75% at the 5-HT_{1D} receptor also had a percent inhibition of less than 60% at the 5-HT_{1B} receptor (for example, compounds of examples 14 and 19d). More preferred compounds showed a percent inhibition of greater
- 30 than 75% at the 5-HT_{1D} receptor and a percent inhibition of less 50% at the 5-HT_{1B} receptor (for example, compounds of examples 19g and 30a).

Example 34 : Functional Assays.

The 5HT_{1D} and 5HT_{1B} receptor subtypes respond to serotonin and other agonists by reducing adenylyl cyclase mediated production of cyclic AMP. Particular test compounds were assayed for their ability to inhibit adenylyl cyclase activity using the procedure described below. Forskolin was used to
5 elevate the basal adenylyl cyclase activity.

Compounds acting as antagonists at the 5HT_{1D} and 5HT_{1B} receptor subtypes will antagonize the agonist effect of serotonin and thus, will block the
10 serotonin-induced inhibition of forskolin-stimulated adenylyl cyclase activity.

CHO Pro 5 cells stably expressing either the human 5HT_{1D} or human 5HT_{1B} receptors were plated in 6 well plates in DMEM (Dulbecco's Modified Eagle Medium)/F12 (Nutrient Mixture F12 – Ham) media with 10% FCS (fetal calf
15 serum) and G418 (Geneticin Disulfate, 500ug/ml), and incubated at 37°C in a CO₂ incubator. The cells were allowed to grow to about 70% confluence before use in the assay.

The culture media of each well was removed, and the wells were washed
20 once with serum free media. Then 2 ml of SFM+IBMX medium (SFM with 0.5 mM IBMX, 3-isobutyl-1-methylxanthine, 0.1% ascorbic acid and 10 mM pargyline) was added to each well and the wells were incubated at 37 °C for 10 min. Following incubation, the SFM+IBMX media was removed from each well and fresh SFM+IBMX media was added to the wells separately with one
25 of a) forskolin (10 mM final concentration); b) serotonin and forskolin (both 10 mM final concentration); c) test compound (100 nM and 10 µM) and forskolin (10 mM final concentration) (to test for agonist activity); and d) test compound (100 nM and 10 µM) along with serotonin and forskolin (both 10 mM final concentration) (to test for antagonist activity). Basal adenylyl cyclase activity
30 was determined from wells with only SFM+IBMX media added.

The cells were then incubated at 37 °C for 30 minutes in a CO₂ incubator. Following incubation, the media were removed from each well. The wells were washed once with 1 ml of PBS (phosphate buffered saline). Each well was then treated with 1 mL cold 95% ethanol:5mM EDTA (2:1) at 4 °C for 1
5 hour. The cells from each well were then scraped and transferred into individual Eppendorf tubes. The tubes were centrifuged for 5 minutes at 4 °C, and the supernatants were transferred to new Eppendorf tubes. The pellets were discarded and the supernatants were stored at 4 °C until assayed for cAMP concentration. cAMP content for each extract was determined in
10 duplicate by EIA (enzyme-immunoassay) using the Amersham Biotrak cAMP EIA kit (Amersham RPN 225).

Total inhibition (I_o) of forskolin-stimulated adenylyl cyclase activity by serotonin was determined as the difference in concentration of cAMP in the forskolin-
15 treated cells (C_f) and serotonin-forskolin treated cells (C_d).

$$I_o = C_f - C_d$$

Likewise, inhibition of forskolin-stimulated adenylyl cyclase activity by an
20 agonist test compound was determined as the difference in concentration of cAMP in the forskolin-treated cells and test compound-forskolin treated cells. Agonist activity is expressed as %forskolin response.

Net inhibition (I) of forskolin-stimulated adenylyl cyclase activity by serotonin in
25 the presence of an antagonist was determined as the difference in concentration of cAMP in the forskolin-treated cells (C_f) and cAMP concentrations in test compound, serotonin and forskolin-treated cells (C).

$$I = C_f - C$$

30

The ability of the test compounds to reverse the serotonin inhibition of forskolin-stimulated adenylyl cyclase activity (% reversal, %R) was determined by the formula:

$$\%R = (1 - I/I_0) \times 100$$

5

Compounds of the invention (such as that of examples 2 and 32) caused a decrease in the forskolin stimulated production of cAMP in CHO cells stably expressing the 5-HT_{1D} receptor, at concentrations of 100 nM and 10 μM, and therefore act as agonists at this receptor.

10

Example 33 : Pharmaceutical Examples.

Tablets

These may be prepared by the normal methods such as wet granulation or direct compression.

15

<i>A. Direct Compression</i>	mg/tablet
Active ingredient	10.0
Microcrystalline Cellulose USP	188.5
Magnesium Stearate BP	1.5
Total weight	200.0

The active ingredient is sieved through a suitable sieve, blended with the excipients and compressed using 7 mm diameter punches. Tablets of other strengths may be prepared by altering the compression weight and using punches to suit.

20

<i>B. Wet Granulation</i>	mg/tablet
Active ingredient	10.0
Lactose BP	143.5
Starch BP	30.0
Pregelatinised Maize Starch BP	15.0
Magnesium Stearate BP	1.5

Total weight	200.0
--------------	-------

- The active ingredient is sieved through a suitable sieve and blended with lactose, starch and pregelatinised maize starch. Suitable volumes of purified water are added and the powders are granulated. After drying, the granules
- 5 are screened and blended with the magnesium stearate. The granules are then compressed into tablets using 7 mm diameter punches.

C. For Buccal Administration	mg/tablet
Active ingredient	10.0
Lactose BP	86.8
Sucrose BP	86.7
Hydroxypropyl methylcellulose	15.0
Magnesium Stearate BP	1.5
Total weight	200.0

- The active ingredient is sieved through a suitable sieve and blended with the
- 10 lactose, sucrose and hydroxypropylmethylcellulose. Suitable volumes of purified water are added and the powders are granulated. After drying, the granules are screened and blended with the magnesium stearate. The granules are then compressed into tablets using suitable punches.
- 15 The tablets may be film-coated with suitable film-forming materials, such as hydroxypropyl methylcellulose, using standard techniques. Alternatively the tablets may be sugar coated.

Capsules

	mg/capsule
Active ingredient	10.0
*Starch 1500	89.0
Magnesium Stearate BP	1.0
Fill Weight	100.0

*A form of directly compressible starch

- The active ingredient is sieved and blended with the excipients. The mix is filled into size No. 2 hard gelatin capsules using suitable machinery. Other doses may be prepared by altering the fill weight and if necessary changing the capsule size to suit.

Syrup

	mg/5 ml dose
Active ingredient	10.0
Sucrose BP	2750.0
Glycerine BP	500.0
Buffer	as required
Flavour	as required
Colour	as required
Preservative	as required
Distilled water	to 5.0 ml

- The active ingredient, buffer, flavour, colour and preservative are dissolved in some of the water and the glycerine is added. The remainder of the water is heated to dissolve the sucrose and is then cooled. The two solutions are combined, adjusted to volume and mixed. The syrup produced is clarified by filtration.

15

Suppositories

Active ingredient	10.0 mg
*Witepsol H15 to	1.0 g

*A proprietary grade of Adeps Solidus Ph. Eur.

- A suspension of the active ingredient in molten Witepsol is prepared and filled, using suitable machinery, into 1 g size suppository moulds.

Injection for Intravenous Administration

	% w/v
Active ingredient	0.2
Sodium Chloride BP	as required
Water for Injection BP	to 100.00

- Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted, using acid or alkali, to that of optimum stability and/or to facilitate solution of the active ingredient. Alternatively suitable buffer salts may be used. The solution is prepared, clarified and filled into appropriate size ampoules sealed by fusion of the glass. The injection is sterilized by heating in an autoclave using one of the acceptable cycles. Alternatively the solution may be sterilized by filtration and filled into sterile ampoules under aseptic conditions. The solution may be packed under an inert atmosphere of nitrogen or other suitable gas.

Inhalation Cartridges

	mg/cartridge
Active ingredient micronised	1.0
Lactose BP	39.0

- The active ingredient is micronised (Microniser is a Registered Trade Mark) in a fluid energy mill to a fine particle size range prior to blending with normal tableting grade lactose in a high energy mixer. The powder blend is filled into No. 3 hard gelatin capsules on a suitable encapsulating machine. The contents of the cartridges are administered using a powder inhaler such as the Glaxo Rotahaler (Registered Trade Mark).

Metered Dose Pressurized Aerosol


	mg/metered dose	per can
Active ingredient, micronised	0.50	120.0 mg
Oleic Acid BP	0.05	12.0 mg
Trichlorofluoromethane BP	22.25	5.34 g

Dichlorofluoromethane BP	62.2	14.92 g
--------------------------	------	---------


The active ingredient is micronised in a fluid energy mill to a fine particle size range. The oleic acid is mixed with the trichlorofluoromethane at a temperature of 10-15 °C and the pulverized drug is mixed into the solution
5 with a high shear mixer. The suspension is metered into aluminum aerosol cans and suitable metering valves, delivering a metered amount of 85 mg of suspension, are crimped onto the cans and the dichlorodifluoromethane is pressure filled into the cans through the valves.

We Claim:


1. A compound selected from the group consisting of a compound of Formula I :




Formula I



Formula II



Formula III



Formula IV

wherein :

W is a CH group or a N atom ;

Z is N or C-R4;

B and D are selected independently from CH and N, with the proviso that at least one of B and D is CH and with the further proviso that one of B and D can represent N only when W and Z are both other than N;

A is a group of Formula II, III or IV, such that group A contains at least 1 N atom ;

NR7 is either -NH- or -N=;

== is a single or double bond ;

X is a N atom, a CH group or a C(OH) group when == is a single bond; or, when

== is a double bond, a C atom ;

Y is an NH, N-alkyl, N-benzyl or CH₂ group ;

U and V each represent a N atom or a CH group, with the proviso that both cannot be N ;

a and b are, independently, 0 or 1 ; c is an integer from 0 to 3 ; d is an integer from 1 to 3 ; e is an integer from 1 to 2 ; f is an integer from 0 to 3 ; g is an integer from 3 to 6 and h is an integer from 2 to 3 ; such that the sum of c and d is at least 2 and the sum of e and f is at least 2;

R₁ is selected from the group consisting of H, alkyl including C(1-12)alkyl alkyloxy, alkanoyl, aminoalkylenyl, alkylaminoalkylenyl, a hydroxyalkylenyl group, an alkyloxyalkylenyl group, a cycloalkyl group, a cycloalkylalkylenyl group, a heterocycloalkyl group, a heterocycloalkylalkylenyl group, an aryl group, a heteroaryl group, an amido group, a thioamido group, an arylcarbonyl group and an arylsulfonyl group ;

R₂ and R₃ are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl and optionally-substituted benzyl ; or R₂ and R₃, together with the nitrogen atom to which they are attached, may form a mono- or bi-cyclic group containing up to 10 carbon atoms and which, in addition, may contain a second heteroatom selected from the group consisting of N, S and O, and which may contain one or more substituents selected from the group consisting of alkyl, hydroxy, hydroxymethyl, alkyloxymethyl, amino and substituted amino ;

R₄ is selected from the group consisting of H, alkyl and cycloalkyl ;

CR₅ represents a group selected from -CH₂-, CH(OH)-, -C(O)-, -CH(alkyl)- and -CH(alkyloxy)- ;

R₆ is selected from the group consisting of H, alkyl, aryl, halogen, hydroxy, alkyloxy, amino, monoalkylamino and di-substitutedalkylamino;

and salts and solvates thereof.

2. A compound according to claim 1 wherein A is a group of Formula II.

3. A compound according to claim 1 wherein A is a group of Formula III.

4. A compound according to claim 1 wherein A is a group of Formula IV.
5. A compound according to claim 2, 3 or 4 wherein R₁ is an aryl group.
6. A compound according to claim 2, 3 or 4 wherein R₁ is a heterocycloalkyl group.
7. A compound according to claim 6 wherein R₁ is tetrahyrdopyranyl.
8. A compound according to claim 2, 3 or 4 wherein R₁ is a cycloalkyl group.
9. A compound according to claim 2, 3 or 4 wherein R₁ is an alkyl group.
10. A compound according to claim 9, wherein R₁ is isopropyl.
11. A compound according to any one of claims 2 and 5-10, wherein A is a group selected from a (mono- or di-) substituted aminoalkylenyl, an N-cycloalkyl and an N-cycloalkylalkylenyl.
12. A compound according to claim 11, wherein A is selected from N,N-dimethylaminoethyl, N,N-diethylaminoethyl, N-methyl-N-ethylaminoethyl, N-isopropylaminoethyl, N,N-dipropylaminoethyl, N-cyclopropylaminoethyl, N-cyclopropylmethylaminoethyl, N-methyl-N-cyclopropylamino, pyrrolidinoethyl, pyrrolinoethyl, piperidinoethyl, morpholinoethyl, thiomorpholinoethyl, piperazinoethyl.
13. A compound according to any one of claims 3 and 5-10, wherein A is a group selected from a 1-azabicyclo[4.3.0]nonanyl group, a 1-azabicyclo[4.4.0]decanyl group, a 1,4-diazabicyclo[4.3.0]nonanyl group or a 1,4-diazabicyclo[4.4.0]decanyl group .

14. A compound according to any one of claims 4 and 5-10, wherein A is selected from (pyrrolidin-2-yl)methyl, N-methyl(pyrrolidin-2-yl)methyl, tetrahydropyridin-4-yl, tetrahydropyridin-3-yl and piperazinyl.
15. A compound according to any preceding claim, wherein the ring system formed by selection of B, D, W and Z is a ring system selected from indole, indoline, indazole, benzotriazole, benzimidazole, 7-aza-indole, and 5-aza-indole.
16. A compound according to claim 15, wherein R6 is selected from H and alkyl, and R4 is H.
17. A compound according to claim 16, wherein the ring system formed by selection of B, D, W, Z, R4 and R6 is selected from indole and indazole.
18. A compound according to claim 16, wherein said ring system is indole.
19. A compound according to claim 1, selected from the group consisting of :
- 6-(2-(N,N-Dimethylamino)ethyl)-1H-indole ;
 - 6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-indole ;
 - 6-(2-(N,N-Diethylamino)ethyl)-indole ;
 - 6-(2-(N,N-Diethylamino)ethyl)-1-isopropyl-indole ;
 - 6-(2-(N,N-Diethylamino)ethyl)-1-dimethylaminocarbonyl-indole ;
 - 6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydrothiopyran-4-yl)-indole ;
 - 6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydropyran-4-yl)-indole ;
 - 6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-1H-indazole ;
 - 6-[4-Hydroxy-azabicyclo[4,3,0]nonan-4-yl]-indole ;
 - 6-[4-Hydroxy-1-methyl-piperidin-4-yl]-indole ;
 - 6-[N-Methyl-1,2,5,6-tetrahydropyridin-4-yl]-indole ;
 - 6-[3,4-Anhydro-azabicyclo[4,3,0]nonan-4-yl]-indole ;
 - 6-[4,5-Anhydro-azabicyclo[4,3,0]nonan-4-yl]-indole ;

6-[N-Methyl-1,2,5,6-tetrahydropyridin-4-yl]-1-isopropyl-indole ;
6-[Azabicyclo[4,3,0]nonan-4-yl]-indole ;
6-[3,4-Anhydro-azabicyclo[4,3,0]nonan-4-yl]-1-isopropyl-indole ;
1-(4-Fluorophenyl)-6-(N-methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole ;
6-[Azabicyclo[4,3,0]nonan-4-yl]-1-isopropyl-indole ;
6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-thienyl)-indole ;
6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-pyridyl)-indole ;
6-[Azabicyclo[4,3,0]nonan-4-yl]-1-(4-pyridinyl)-indole ;
6-(2-Dimethylaminoethyl)-1-(3-pyridinyl)-indole ;
6-(2-Dimethylaminoethyl)-1-(3-thienyl)-indole ;
6-(2-Dimethylaminoethyl)-1-(4-fluorophenyl)-indole ;
6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(2-thiazolyl)-indole ;
1-Dimethylaminocarbonyl-6-[N-methyl-1,2,5,6-tetrahydro-pyridin-4-yl]-indole ;
6-[4-Hydroxy-1-methyl-piperidin-4-yl]-1-isopropyl-indole ;
6-((N-Benzyloxycarbonyl)proyl)-indole ;
6-[(α -Hydroxy- α -(2-Pyrrolidinyl))methyl]-indole ;
6-((2-Pyrrolidinyl)methyl)-indole ;
6-(3-methylpiperazinyl)-1-triisopropylsilyl-indole ;
6-(N-methylpiperazinyl)-indole ;
1-Isopropyl-6-(N-methylpiperazinyl)-indole ;
1-Isopropyl-6-(N-methylhomopiperazinyl)-indole ;
6-(1,3-Diazabicyclo-[4,4,0]-decan-3-yl)-1-isopropyl-indole ;
1-Isopropyl-6-(3-methylpiperazinyl)-indole ;
1-Isopropyl-6-(4-methylpiperazinyl)-indole ;
1-(4-Fluorophenyl)-6-(4-methylpiperazinyl)-indole ;
6-(4-Methylpiperazinyl)-1-(3-thiazolyl)-indole and
6-(4-Methylpiperazinyl)-1-(3-thienyl)-indole.

20. A compound according to claim 19, selected from the group consisting of
:

6-[4-Hydroxy-1-methyl-piperidin-4-yl]-indole ;

6-[N-Methyl-1,2,5,6-tetrahydropyridin-4-yl]-indole ;
6-[N-Methyl-1,2,5,6-tetrahydropyridin-4-yl]-1-isopropyl-indole ;
1-(4-Fluorophenyl)-6-(N-methyl-1,2,5,6-tetrahydropyridin-4-yl)-indole ;
6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-thienyl)-indole ;
6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(3-pyridyl)-indole ;
6-(N-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-1-(2-thiazolyl)-indole ;
1-Dimethylaminocarbonyl-6-[N-methyl-1,2,5,6-tetrahydro-pyridin-4-yl]-indole ;
6-[4-Hydroxy-1-methyl-piperidin-4-yl]-1-isopropyl-indole ;
6-((N-Benzyloxycarbonyl)propyl)-indole ;
6-[(α -Hydroxy- α -(2-pyrrolidinyl))methyl]-indole ;
6-((2-Pyrrolidinyl)methyl)-indole ;
6-(N-Methylpiperazinyl)-indole ;
1-Isopropyl-6-(N-methylpiperazinyl)-indole ;
1-Isopropyl-6-(N-methylhomopiperazinyl)-indole ;
1-Isopropyl-6-(3-methylpiperazinyl)-indole ;
1-Isopropyl-6-(4-methylpiperazinyl)-indole ;
1-(4-Fluorophenyl)-6-(4-methylpiperazinyl)-indole ;
6-(4-Methylpiperazinyl)-1-(3-thiazolyl)-indole and
6-(4-Methylpiperazinyl)-1-(3-thienyl)-indole.

21. A compound according to claim 20, selected from the group consisting of :

6-(2-(N,N-Dimethylamino)ethyl)-1H-indole ;
6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-indole ;
6-(2-(N,N-Diethylamino)ethyl)-1-isopropyl-indole ;
6-(2-(N,N-Diethylamino)ethyl)-1-dimethylaminocarbonyl-indole ;
6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydrothiopyran-4-yl)-indole ;
6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydropyran-4-yl)-indole ;
6-(2-(N,N-Dimethylamino)ethyl)-1-(3-pyridinyl)-indole ;
6-(2-(N,N-Dimethylamino)ethyl)-1-(3-thienyl)-indole and
6-(2-(N,N-Dimethylamino)ethyl)-1-(4-fluorophenyl)-indole.

22. A composition comprising a compound according to any preceding claim, and a carrier.
23. A composition comprising a therapeutically effective amount of a compound according to any preceding claim, and a pharmaceutically acceptable carrier.
24. A method for treating a patient having a medical condition for which stimulation of the 5-HT_{1D} receptor is indicated, comprising the step of administering to the patient a pharmaceutical composition as defined in claim 23.
25. A method for treating a patient according to claim 24, wherein the medical condition is migraine.